JOINT FAO/WHO FOOD STANDARDS PROGRAMME

CODEX ALIMENTARIUS COMMISSION
   Twenty-second Session

REPORT OF THE NINTH SESSION OF THE
CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS
Washington, D.C., USA
5 - 8 December 1995
SUMMARY AND CONCLUSIONS

The Ninth Session of the Codex Committee on Residues of Veterinary Drugs in Foods reached the following conclusions:

MATTERS FOR CONSIDERATION BY THE COMMISSION OR ITS EXECUTIVE COMMITTEE

- Recommended for adoption at Step 8, the Draft Maximum Residue Limits for levamisole (liver/cattle, sheep, pigs) and for triclabendazole (muscle/cattle; liver and kidney/cattle; and muscle, liver and kidney/sheep) (paras. 29-30; Appendix II);
- Recommended for adoption at Step 5 by the Executive Committee, the Proposed Draft Maximum Residue Limits for carazolol, ceftiofur sodium, doramectin, moxidectin and spiramycin (paras. 34, 36, 41-42 & 44; Appendix IV);
- Agreed on a Priority List of Veterinary Drugs Requiring Evaluation or Reevaluation (paras. 57-59; Appendix VI);
- Agreed to amend the previously recommended methods of analysis for the existing Codex Maximum Residue Limits for Veterinary Drugs (paras. 48; Appendix VII); and
- Proposed to elaborate guidelines on residues at injection sites (paras. 26, 66).

OTHER MATTERS OF INTEREST TO THE COMMISSION

- Agreed that at this stage the Committee did not wish to provide further input on the Programme Area of biotechnology to the Commission; however, expressed interest in reviewing future documents on this issue (para. 6);
- Decided to review the Codex Guidelines for the Establishment of a Regulatory Programmes for Control of Veterinary Drug Residues in Foods to assess whether these address appropriately the issue of control of veterinary drug residues in raw milk and milk products (para. 9);
- Supported the incorporation of a science-based approach to risk analysis into its work and agreed that a discussion paper should be for consideration at its 10th Session (para. 14);
- Strongly supported the creation of an International Cooperation on the Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (para. 22);
- Requested a paper containing guidance for determining the classes or formulations of drugs that would cause problems relating injection site residues and proposed draft guidelines for dealing with injection site residues (para. 26);
- Decided that that if no method of analysis acceptable to the Committee was recommended to monitor an MRL, the MRL should not be advanced beyond Step 7 and reaffirmed that temporary MRLs should be retained at Step 4 (paras. 27 & 32);
- Retained at Step 7 the Draft Maximum Residue Limits for levamisole (muscle, kidney, fat/cattle, cheep, pigs, poultry; and liver/poultry); for triclabendazole (fat/cattle, sheep); and for diminazene (all) as they were not supported by methods of analysis (paras. 28 & 30-31; Appendix III);
- Retained at Step 4 all temporary MRLs for apaperone, carazolol, chlortetracycline/tetracycline, dexamethasone, diclazuril, dihydrostreptomycin/streptomycin, febantel/fenbendazole/oxfendazole, gentamicin, moxidectin, neomycin, oxytetracycline, spectinomycin and spiramycin (paras. 34, 36, 39, 42 & 45; Appendix V);

- Agreed to withdraw the MRL for levamisole in milk (para. 40);

- Made a series of recommendations on methods of analysis (para. 48):
  - Supported the proposal that greater emphasis should be given to the availability of analytical methods for compounds to be considered for JECFA evaluation (para. 49);
  - Agreed that MRLs should be developed independently of validated methods (para. 54);
  - Requested a paper for consideration at its next Session on the criteria for validated analytical methods (para. 54); and
  - Agreed that a progress report on the Compendium of Veterinary Drugs would be presented at its next Session (para. 63).
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Paragraphs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
</tr>
<tr>
<td><strong>OPENING OF THE SESSION</strong></td>
<td></td>
</tr>
<tr>
<td><strong>ADOPTION OF THE AGENDA</strong></td>
<td></td>
</tr>
<tr>
<td><strong>APPOINTMENT OF RAPPORTEUR</strong></td>
<td></td>
</tr>
<tr>
<td><strong>MATTERS REFERRED TO THE COMMITTEE</strong></td>
<td></td>
</tr>
<tr>
<td>- Matters Arising from the Codex Alimentarius Commission and Other Codex Committees</td>
<td>5 - 9</td>
</tr>
<tr>
<td>- Risk Assessment/Analysis in Codex: Recommendations of the FAO/WHO Expert Consultation</td>
<td>10 - 14</td>
</tr>
<tr>
<td><strong>REPORT OF THE FORTY-THIRD AND FORTY-FIFTH JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES</strong></td>
<td>15 - 20</td>
</tr>
<tr>
<td><strong>REPORT FROM OIE ON THE PROPOSED INTERNATIONAL COOPERATION ON HARMONIZATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF VETERINARY MEDICINAL PRODUCTS</strong></td>
<td>21 - 23</td>
</tr>
<tr>
<td><strong>CONSIDERATION OF INJECTION SITE RESIDUES OF VETERINARY DRUGS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CONSIDERATION OF DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS AT STEP 7</strong></td>
<td>27 - 31</td>
</tr>
<tr>
<td><strong>CONSIDERATION OF PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS AT STEP 4 ARISING FROM THE 43RD AND 45TH JECFA AND THOSE RETAINED AT STEP 4</strong></td>
<td>32 - 44</td>
</tr>
<tr>
<td><strong>CONSIDERATION OF METHODS OF ANALYSIS AND SAMPLING FOR VETERINARY DRUG RESIDUES IN FOODS</strong></td>
<td>47 - 54</td>
</tr>
<tr>
<td><strong>CONSIDERATION OF THE PRIORITY LIST OF VETERINARY DRUGS REQUIRING EVALUATION OR REEVALUATION</strong></td>
<td>55 - 61</td>
</tr>
<tr>
<td><strong>PROGRESS REPORT ON THE COMPENDIUM OF VETERINARY DRUGS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>OTHER BUSINESS AND FUTURE WORK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>DATE AND PLACE OF NEXT SESSION</strong></td>
<td></td>
</tr>
</tbody>
</table>

**LIST OF APPENDICES**

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Page Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix I</td>
<td>LIST OF PARTICIPANTS</td>
</tr>
<tr>
<td>Appendix II</td>
<td>DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS ADVANCED TO STEP 8</td>
</tr>
<tr>
<td>Appendix III</td>
<td>DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS RETAINED AT STEP 7</td>
</tr>
<tr>
<td>Appendix IV</td>
<td>PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS ADVANCED TO STEP 5</td>
</tr>
<tr>
<td>Appendix V</td>
<td>PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS RETAINED AT STEP 4</td>
</tr>
<tr>
<td>Appendix VI</td>
<td>PRIORITY LIST OF VETERINARY DRUGS REQUIRING EVALUATION OR REEVALUATION</td>
</tr>
<tr>
<td>Appendix VII</td>
<td>AMENDMENTS OF METHODS OF ANALYSIS FOR EXISTING CODEX MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS</td>
</tr>
<tr>
<td>Appendix VIII</td>
<td>LIST OF VETERINARY DRUGS EVALUATED BY JECFA ON WHICH NO ACTION HAS BEEN TAKEN BY THE COMMITTEE</td>
</tr>
</tbody>
</table>
REPORT OF THE NINTH SESSION OF THE CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS

INTRODUCTION

1. The Codex Committee on Residues of Veterinary Drugs in Foods held its Ninth Session from 5 to 8 December 1995 in Washington, D.C., at the kind invitation of the Government of the United States of America. The Session was chaired by Dr. Stephen Sundlof, Director, Center for Veterinary Medicine, United States Food and Drug Administration. The Session was attended by 47 member countries, 1 observer country and 10 international organizations. A list of participants, including members of the Secretariat, is attached to this report as Appendix I.

OPENING OF THE SESSION (Agenda Item 1)

2. The Committee was addressed by Mr. Michael R. Taylor, Acting Under Secretary for Food Safety. The subject of his speech was “Accomplishments and Challenges for the Future”. Mr. Taylor stressed the importance of Codex Alimentarius Commission in addressing food safety and stated that the future challenges for the Codex Alimentarius Commission and this Committee were great. He pointed out the need to base Codex standards on science; to involve the public more fully; to revitalize Codex through strategic planning and ensuring a more efficient standard setting process; and to support the incorporation of risk assessment principles into the Codex process.

ADOPTION OF THE AGENDA (Agenda Item 2)

3. The Committee adopted the Provisional Agenda with the understanding that Agenda Item 10 should be considered immediately before Agenda Item 8 in order to facilitate discussion on Maximum Residue Limits.

APPOINTMENT OF RAPPORTEUR (Agenda Item 3)

4. The Committee appointed Dr. J.M. Rutter (United Kingdom) to serve as Rapporteur for this Session.

MATTERS REFERRED TO THE COMMITTEE

MATTERS ARISING FROM THE CODEX ALIMENTARIUS COMMISSION AND OTHER CODEX COMMITTEES (Agenda Item 4(a))

5. The Codex Alimentarius Commission, at its 21st Session, had approved the strategic planning approach for implementing the Medium-Term Plan. It had also approved the Project Plans submitted to it and requested the relevant Committees to take immediate action as required in respect of the Project Plans. The CCRVDF had been identified as being involved in the Programme Areas of risk analysis and biotechnology.

---

1 CX/RVDF 95/2, Conference Room Document (CRD) 2 (comments from the Consumer International).
2 See Agenda Item 4(b).
6. Following discussion of the proposed Project Plans for biotechnology, the Committee agreed that at this stage it did not wish to provide further input to the Commission. However, it expressed interest in reviewing future documents on this issue.

RESIDUES OF VETERINARY DRUGS IN MILK AND MILK PRODUCTS

7. The Codex Committee on Milk and Milk Products, at its First Session, had considered the contaminant provisions in revised standards and recognized that veterinary drugs could be carried over from raw milk into processed products. It had requested the CCRVDF to consider whether this should be specifically taken into account and, if so, how.

8. Many delegations stated that setting MRLs for raw milk was sufficient to control residues of veterinary drugs in milk and milk products as monitoring of residues was most efficient and effective at as early a stage as possible in the food processing chain. However, it was pointed out that milk and milk products are ingested by susceptible populations, including babies and infants, which might lead to health concerns.

9. After some discussion, the Committee decided to accept the offer of the Delegation of the United States, with assistance provided by France, Switzerland, Thailand and the United Kingdom, to review the Codex Guidelines for the Establishment of a Regulatory Programme for Control of Veterinary Drug Residues in Foods to assess whether these address appropriately the issue of control of veterinary drug residues in raw milk and milk products and to prepare a paper for consideration at the 10th Session.

RISK ASSESSMENT/ANALYSIS IN CODEX: RECOMMENDATIONS OF THE JOINT FAO/WHO EXPERT CONSULTATION (Agenda Item 4(b))

10. The Committee noted that the 21st Session of the Codex Alimentarius Commission had considered the report of the Joint FAO/WHO Expert Consultation on the Application of Risk Analysis to Food Standards Issues, which was held in Geneva from 13-17 March 1995.

11. The Commission had agreed that there was a need for further clarification of terms and definitions used for risk analysis and comments were subsequently solicited under circular letter CL 1995/40-CAC. This drew the attention of governments to amendments proposed for the terms risk communication (to include explicit reference to consumers), risk assessment (to include reference to severity of effects) and risk characterization (to include reference to probability).

12. The Commission had also recommended further work on risk management, risk communication and definition of the roles and responsibilities of the different bodies involved in risk analysis as well as on the uncertainty and variability in risk analysis in relation to standard setting and food regulation.

13. The Commission had agreed that the Report and recommendations of the Consultation should be examined by relevant Codex committees, including the Codex Committee on Residues of Veterinary Drugs in Foods. The Commission had also noted the problems of developing countries in regard to implementing the risk analysis approach in their food regulations.

14. The Committee supported the incorporation of a science-based approach to risk analysis into its work, and agreed that a discussion paper would be developed under the direction of France, with

---

3 CX/RVDF 95/3 and CRD 2 (comments from Consumers International).
4 ALINORM 95/37, paras. 27-30 and ALINORM 95/9.
5 WHO/FNU/FOS/95.3.
assistance provided by Australia, Canada, the Netherlands, New Zealand, Norway and the United States, for consideration at its 10th session. The paper should address the possible implementation of the recommendations of the FAO/WHO Expert Consultation on the Application of Risk Analysis to Food Standards Issues as they applied to the work of CCRVDF, and to consider initiatives undertaken by other Codex committees.

REPORT OF THE FORTY-THIRD AND FORTY-FIFTH JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES (Agenda Item 5)

15. The FAO and WHO Joint Secretaries of JECFA summarized the results of the 43rd and 45th Joint FAO/WHO Expert Committee on Food Additives (JECFA).

16. Ten veterinary drugs had been on the agenda of the Forty-third meeting for evaluation. Acceptable daily intakes (ADIs) and maximum residue limits (MRLs) had been allocated to carazolol and to spiramycin, for which the MRLs for pig tissues except muscle are temporary. Temporary ADIs and MRLs had been established for dihydrostreptomycin and streptomycin (group ADI), gentamicin, neomycin, and azaperone. A temporary ADI had been allocated to enrofloxacin, but MRLs had not been allocated due to insufficient data. For dexamethasone, temporary MRLs had been established, the ADI having been allocated at the Forty-second meeting of the Committee.

17. Eleven veterinary drugs had been on the agenda of the Forty-fifth meeting for evaluation. ADIs and MRLs had been allocated to moxidectin, for which MRLs for deer are temporary, doramectin, and ceftiofur sodium. Temporary ADIs and MRLs had been established for diclazuril and for febantel, fenbendazole and oxfendazole (group ADI). A group ADI and temporary MRLs had been allocated to chlortetracycline, oxytetracycline and tetracycline. An ADI for abamectin, taking into consideration the presence of its Δ8,9-isomer when used as an insecticide in plants, had been established by the Joint Meeting on Pesticide Residues (JMPR) but MRLs had not been recommended by JECFA because of differences in the way abamectin is metabolized in plants and animals, and differences in the estimation of intakes of residues by JMPR and JECFA. A subsequent meeting between representatives of JECFA and JMPR had recognized a need to harmonize the JECFA and JMPR assessments and proposed to continue to explore ways to do so. The 1995 JMPR established a separate ADI for abamectin itself that should be appropriate for comparison with the theoretical maximum daily intake when it is used as a veterinary drug.

18. A working paper on the microbiological assessment of veterinary drug residues in food had been considered at the Forty-fifth meeting of JECFA. The meeting had recommended that the paper be distributed to interested organizations and governments for comments. A revised paper had been circulated, and comments were being requested by 1 February 1996. These comments and suggestions would be used in developing approaches for future assessments.

19. The Vice-Chairman of the Forty-third and Forty-fifth meetings of JECFA, Dr. J. Boisseau, informed the Committee that JECFA, in its Forty-fifth report, had considered (1) an integrated approach to risk assessment that includes all potential sources of intake including consumer exposure from veterinary drug use, plant protection use, and, when applicable and appropriate methodologies are available, possible recycling through excreta that may be spread on land or recycled into food for other species, (2) sampling procedures for analyzing the injection site, and (3) the need to ensure that account has been taken of potential loss of analyte during the extraction, clean-up, and determination of the veterinary drug.

---

INACTIVE LIST

20. In response to a request by the European Community (EC) to improve the dissemination of information and to include additional information for substances placed on the "Inactive List" maintained by the CCRVDF, the Codex Secretariat indicated that JECFA reports included reasons why ADIs or MRLs had not been allocated and were circulated to all Codex Contact Points. Nevertheless in order to improve the circulation of such information important for protection of human health, the EC proposed that these reasons should be also included in the JECFA summary reports and in the relevant appendices of the reports of the meeting.

REPORT FROM OIE ON THE PROPOSED INTERNATIONAL COOPERATION ON HARMONIZATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF VETERINARY MEDICINAL PRODUCTS (Agenda Item 6)\(^7\)

21. The representative of the International Office of Epizootics (OIE) reported on a proposal to establish an International Cooperation on the Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) under the auspices of OIE and with the collaboration of COMISA. The proposed VICH is being developed in response to a need to harmonize, on an international basis, the technical requirements to be fulfilled by the veterinary pharmaceutical industry for drug registration. The advantages expected from such an international harmonization included greater efficiency and effectiveness for both industry and the competent authorities in the registration of veterinary products, without compromising safety, efficacy and quality.

22. The Committee strongly supported the creation of VICH since the technical requirements of veterinary drug registration were not normally considered by the CCRVDF. The Committee noted that the proposed VICH would complement and not duplicate related Codex activities, and asked OIE to report progress to future meetings of the CCRVDF.

23. The Committee thanked the representative of the OIE for his presentation.

CONSIDERATION OF INJECTION SITE RESIDUES OF VETERINARY DRUGS (Agenda Item 7)\(^8\)

24. The Delegation of Australia presented the paper prepared after consulting with France, New Zealand, United Kingdom, United States, the European Commission and COMISA. The objectives of the paper had been: to identify the extent of problems in relation to injection site residues; to review the different ways these problems were being addressed and the need for harmonization; and to propose how to proceed.

25. Several Delegations shared the concerns identified in the paper about possible health risks posed by ingesting meat containing injection site residues and the implications of such residues for international trade of meat. It was noted that potential problems could arise from the use of drugs with acute toxicity or potent pharmacological activity, or those causing allergic reactions.

26. The Committee requested the Delegation of Australia, in collaboration with Canada, France, Germany, New Zealand, Switzerland, United Kingdom, United States, the EC and COMISA, to prepare a paper for consideration by the Committee at its next session. The paper should include guidance for determining the classes or formulations of drugs that would cause such problems and

\(^7\) CX/RVDF 95/4.
\(^8\) CX/RVDF 95/5, CRD 2 (comments from Consumer International).
proposed draft guidelines for dealing with injection site residues. The principles of risk analysis should be considered in addressing these issues.

CONSIDERATION OF DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS AT STEP 7 (Agenda Item 8)

27. The Committee decided that if no method of analysis acceptable to the Committee was recommended to monitor an MRL, the MRL should not be advanced beyond Step 7.

Triclabendazole

28. The MRLs for triclabendazole had been retained at Step 7 since the 8th Session as further data related to toxicity and total residues distribution and depletion had been likely to become available. No data had been submitted to JECFA but it was reported that new data were being developed by the manufacturer.

29. The Committee decided to advance the MRLs for muscle (cattle); liver and kidney (cattle); and muscle, liver and kidney (sheep) to Step 8 with the understanding that when new data became available they should be evaluated by JECFA. The MRL for fat (cattle, sheep) was retained at Step 7, as there was no recommended method of analysis.

Levamisole

30. The Committee decided to advance the MRL for liver (cattle, sheep, pigs) to Step 8 and to retain those for muscle, kidney, fat (cattle, sheep, pigs, poultry) and for liver (poultry) at Step 7 as these were not supported by methods of analysis.

Diminazene

31. The Committee decided to retain the MRLs for diminazene at Step 7 as they were not supported by methods of analysis. The Committee noted that a method of analysis was being developed by the manufacturer, and agreed that if the method was found satisfactory at its next session, the Committee would consider advancing the MRLs to Step 8.

CONSIDERATION OF PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS AT STEP 4 ARISING FROM THE 43RD AND 45TH JECFA AND THOSE RETAINED AT STEP 4 (Agenda Item 9)

32. The Committee reaffirmed its previous decision that temporary MRLs should be retained at Step 4. The Committee also reiterated that if no method of analysis acceptable to the Committee was recommended to monitor an MRL, the MRL should not be advanced beyond Step 7.

---

9 Appendices III & IV of ALINORM 95/31, CL 1995/21-RVDF, CX/RVDF 95/6 (comments from Czech Republic and France), CRD 1 (comments from the EC). See also Appendices II & III of this report.

10 ALINORM 95/31, Appendix V (MRLs retained at Step 4); CL 1995/1-RVDF (MRLs arising from 43rd JECFA); CL 1995/21-RVDF (MRLs arising from 45th JECFA); CX/RVDF 95/7 (comments from Canada, Czech Republic, France and Spain); and CRD 1 (comments from the EC). Also see Appendices IV and V of this report.
Carazolol

33. The Committee was informed that the 43rd JECFA allocated a full ADI of 0-0.1 µg/kg body weight. The 43rd JECFA converted the MRL for pig muscle and fat/skin (5 µg/kg) to full status and lowered the MRL for pig liver and kidney to 25 µg/kg (full status).

34. The MRL for pig liver and kidney were advanced to Step 5. The MRL for pig muscle and fat/skin were also advanced to Step 5, with the understanding that suitable methods of analysis would be identified prior to their final adoption at Step 8.

Spiramycin

35. The Committee noted that the 43rd JECFA allocated a full ADI of 0-50 µg/kg body weight.

36. The full MRLs for cattle muscle, liver, kidney, fat and milk; chicken muscle, liver, kidney and fat; and pig muscle were advanced to Step 5. The temporary MRLs for pig liver, kidney and fat were retained at Step 4.

37. Suitable methods of analysis were required prior to their final adoption at Step 8 for full MRLs for pig muscle and for cattle milk and temporary MRLs for pig liver, kidney and fat.

Febantel/Fenbendazole/Oxfendazole

38. The 45th JECFA lowered the temporary group ADI to 0-4 µg/kg body weight.

39. The temporary MRLs for febantel, fenbendazole and oxfendazole were all retained at Step 4. Suitable methods of analysis were required to support temporary MRLs for kidney and fat (cattle, pigs, sheep) and for milk (cattle).

Levamisole

40. The 42nd JECFA had withdrawn the temporary MRL for cattle milk and the Committee agreed to withdraw the milk MRL for levamisole.

Doramectin

41. The 45th JECFA allocated full MRLs for cattle muscle, liver, kidney and fat. These were advanced to Step 5, with the understanding that suitable methods of analysis would be identified prior to their final adoption at Step 8.

Moxidectin

42. The 45th JECFA allocated full MRLs for muscle, liver, kidney and fat (cattle and sheep) and temporary MRLs for deer muscle, liver, kidney and fat. The Committee advanced all full MRLs to Step 5 and retained temporary MRLs for deer at Step 4. The Committee noted that suitable methods of analysis should be identified prior to their final adoption at Step 8.

43. The Delegation of Australia noted that residues in cattle fat could exceed the MRL due to uses involving multiple administration for tick control. It was agreed that the data would be provided to JECFA.
Ceftiofur sodium

44. The 45th JECFA allocated full MRLs for muscle, liver, kidney and fat (cattle and pigs) and cattle milk. The Committee advanced all these to Step 5 and noted that suitable methods of analysis were required for all MRLs prior to their final adoption at Step 8.

Azaperone/Chlortetracycline and tetracycline/Dexamethasone/Diclazuril/Dihydrostreptomycin and streptomycin/Gentamicin/Neomycin/Oxytetracycline/Spectinomycin

45. JECFA had set temporary MRLs for all these substances which the Committee agreed should be retained at Step 4. The Committee noted that there had been several Codex MRLs for certain animal products established for oxytetracycline and that the temporary MRL for oxytetracycline was for giant prawns.

46. Suitable analytical methods were required for MRLs for the following:

- azaperone: fat (pigs);
- chlortetracycline/tetracycline: liver (cattle, pigs, sheep, poultry) and eggs (poultry);
- dexamethasone: all MRLs;
- dihydrostreptomycin/streptomycin: all MRLs;
- gentamicin: fat (cattle, pigs) and milk (cattle);
- neomycin: muscle and fat (cattle, chickens, ducks, goats, pigs, sheep, turkeys); liver and kidney (chickens, ducks, goats, sheep, turkeys); eggs (chickens); and milk (cattle);
- oxytetracycline: giant prawn; and
- spectinomycin: muscle, liver, kidney and fat (cattle, chickens, pigs) and milk (cattle).

CONSIDERATION OF METHODS OF ANALYSIS AND SAMPLING FOR VETERINARY DRUG RESIDUES IN FOODS (Agenda Item 10)


47. The Chairman of the Working Group, Dr. R. Ellis (USA), presented the report of the Group.

48. The Committee agreed to give full recommendation to the method for sulfadimidine in cattle milk and provisional status to methods for azaperone/azaperol in pig tissues (3 methods); for chlortetracycline/oxytetracycline/tetracycline in muscle and kidney of cattle, pig and poultry and in cattle milk; for diclazuril in muscle, liver, kidney and fat of rabbit, sheep and poultry; for gentamicin in muscle, liver and kidney of cattle and pig; for isometamidium in muscle, liver, kidney and fat of cattle; for levamisole in pig liver, in liver of cattle, pig and sheep and in cattle milk; for neomycin in liver and kidney of cattle and pig; and for spiramycin/neospiramycin in muscle, liver, kidney and fat of cattle and poultry. The Committee also agreed to delete provisionally recommended methods for albendazole in muscle, fat and milk; carbadox in muscle; chloramphenicol (4 methods) in muscle, milk and eggs; and trenbolone in muscle and liver because of the lack of multi-laboratory validation studies.

---

11 CX/RVDF 95/8, CRD 3 (CX/RVDF 95/8-Add.2).
12 See Appendices III-V and VII of this report for detailed references.
The Committee supported the proposal that greater emphasis should be given to the availability of analytical methods for compounds to be considered for JECFA evaluation.

The Group expressed its serious concern about the proposal of the Codex Committee on Methods of Analysis and Sampling that reference methods for Codex standards required validation by a minimum of six laboratories. The Committee noted that it had been difficult for analytical methods for veterinary drug residues to be validated by a minimum of three laboratories.

The Committee thanked the Working Group and its Chairman and agreed to set up the ad hoc Working Group under Dr. R. Ellis (USA) at its next session.

Establishing Routine Methods to Meet Codex MRL Requirements

The Delegation of Australia introduced the paper and proposed that a country nominating a substance for inclusion in the priority list should commit itself to identify or develop a suitable validated method(s) of analysis to support MRLs. Many delegations expressed concern about the lack of validated methods to support Codex MRLs and of harmonized methods for regulatory purposes. In the case of older drugs, there had been special problems as sometimes sponsors were not identified or some methods available might use unacceptable reagents.

The Committee's discussion mainly covered matters related to the availability and validation of methods, and whether an MRL needed to be set before a method could be recommended. The Committee noted that methods of analysis included in the submission to JECFA might be suitable for regulatory purposes but were not in the public domain. Furthermore, such methods would require inter-laboratory validation and to be available to regulatory authorities to be recommended for Codex purposes.

The Committee agreed that MRLs should be developed independently of validated methods, but such methods should be available before the Committee advances MRLs to Step 8. The Committee requested the Delegation of Australia, in collaboration with Canada, France, Germany, the Netherlands, United Kingdom, United States, COMISA and IDF to prepare a paper for consideration at the next session to help the Committee decide how best to proceed in the light of the points raised. The paper should include the criteria for a validated analytical method, how such a method should be developed in relation to the Codex Step Procedure, and the responsibilities of countries, manufacturers and other bodies involved. Input from the JECFA Secretariat should be sought. The FAO Joint Secretary of JECFA undertook to identify appropriate methods of analysis in previous submissions to JECFA.

Consideration of the Priority List of Veterinary Drugs Requiring Evaluation (Agenda Item 11)

The Chairman of the ad hoc Working Group, Dr. J. Owusu (Australia), introduced the report and recommendations of the Group.

Australia, Brazil, Malaysia and Switzerland had recommended fluazuron to be included in the priority list and the European Community recommended cyfluthrin, cyhalothrin, danofloxacin, deltamethrin, florfenicol, griseofulvin, marbofloxacin, metrifonate, permethrin, phoxim, and...
sarafloxacin. Commitments were made by manufacturers for the provision of relevant data on cyfluthrin, danofloxacin and fluazuron in time for evaluation by the Forty-eighth meeting of JECFA in 1997, while the data for metrifonate would be available for evaluation at the Fiftieth meeting in 1998.

57. The Committee agreed to add cyfluthrin, danofloxacin, fluazuron and metrifonate to the priority list. It noted that cyfluthrin had already been evaluated by JMPR so its review would require close cooperation between JECFA and JMPR.

58. It was confirmed that data on apramycin would not be available in the near future and this substance was removed from the priority list. Nicarbazin was retained on the priority list pending the availability of data.

59. The provisional agendas for the Forty-eighth (February 1997) and Fiftieth (February 1998) meetings of JECFA are listed in Appendix VI. The agendas include substances that require re-evaluation for a number of reasons. Fluazuron, cyfluthrin and danofloxacin were added to the agenda of the Forty-eighth meeting of JECFA, and metrifonate was added to the agenda of the Fiftieth meeting of JECFA.

60. It was emphasized that following the recent GATT/WTO agreements, Codex standards had become important in resolving trading disputes. It was important that nominations continued to come forward and that these conformed with the criteria for inclusion on the priority list.

61. The Committee thanked the Working Group, its Chairman and the rapporteur for its work and agreed to set up the ad hoc Working Group at its next session under Dr. J. Owusu (Australia).

PROGRESS REPORT ON THE COMPENDIUM OF VETERINARY DRUGS (Agenda Item 12)

62. The Delegation of the United States reported that with the collaboration of 79 countries the revised 5th edition of the Compendium of Regulations and Authorities for Registered Veterinary Products had been prepared and published in both hard copy and electronic form. The 6th edition would be made available on a global basis through the Internet and World-Wide Web in March 1996.

63. The Committee expressed its appreciation to the United States for its efforts, and agreed that a progress report would be presented at its next session.

OTHER BUSINESS AND FUTURE WORK (Agenda Item 13)

OTHER BUSINESS

64. The Delegation of New Zealand suggested that the current policy for elaborating species specific MRLs be reconsidered as this policy is not based on any human health rationale and restricts the usefulness of these standards for non-specified species. As the average daily intake of meat and offal used in elaborating MRLs does not differentiate between species, then MRLs should also be species generic, unless a technical justification for a difference exists.

65. New Zealand also reiterated that MRLs should be based not on notional zero risk but on a thorough risk analysis and that strict accept/reject criteria relating to MRLs should only be applied to products when there is evidence of acute toxicological effects. The Delegation of France agreed to
consider this issue when developing the discussion paper on risk analysis as related to the establishment of MRLs.  

**FUTURE WORK**

66. The Committee noted that the proposed elaboration of Guidelines on Residues at Injection Sites was subject to approval by the 43rd Session of the Executive Committee.

**DATE AND PLACE OF NEXT SESSION (Agenda Item 14)**

67. The Committee was informed that its tenth session was tentatively scheduled to be held from 29 October - 1 November 1996. The possibility of holding the meeting in a developing country was also under consideration, subject to further discussion by the Codex and Host Government Secretariats.

---

17 See Agenda Item 4(b).
18 See Annex of this report.
19 See Agenda Item 7.
<table>
<thead>
<tr>
<th>Subject</th>
<th>Step</th>
<th>Step Details</th>
<th>Document Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draft Maximum Residue Limits for Veterinary Drugs</td>
<td>8</td>
<td>22nd CAC</td>
<td>Appendix II</td>
</tr>
<tr>
<td>Proposed Draft Maximum Residue Limits for Veterinary Drugs</td>
<td>5</td>
<td>43rd Executive Committee</td>
<td>Appendix IV</td>
</tr>
<tr>
<td>Draft Maximum Residue Limits for Veterinary Drugs</td>
<td>7</td>
<td>JECFA CCRVDF</td>
<td>Appendix III</td>
</tr>
<tr>
<td>Proposed Draft Maximum Residue Limits for Veterinary Drugs</td>
<td>4</td>
<td>JECFA CCRVDF</td>
<td>Appendix V</td>
</tr>
<tr>
<td>Priority List of Veterinary Drugs Requiring Evaluation</td>
<td>1</td>
<td>43rd Executive Committee Governments JECFA CCRVDF</td>
<td>Appendix VI, paras. 57-59</td>
</tr>
<tr>
<td>Guidelines on Residues at Injection Sites (and other matters related to injection site residues)</td>
<td>1</td>
<td>43rd Executive Committee Australia Canada, France, Germany, New Zealand, Switzerland, UK, USA, EC, COMISA 10th CCRVDF</td>
<td>para. 26</td>
</tr>
<tr>
<td>Methods of Analysis and Sampling</td>
<td>-</td>
<td>22nd CAC Governments CCRVDF</td>
<td>Appendix VII, Appendix II-V, para. 48</td>
</tr>
<tr>
<td>Establishing Routine Methods to Meet Codex MRL Requirements</td>
<td>-</td>
<td>Australia Canada, France, Germany, the Netherlands, UK, USA, COMISA, IDF JECFA CCRVDF</td>
<td>para. 54</td>
</tr>
<tr>
<td>List of Veterinary Drugs Evaluated by JECFA on Which No Action Has Been Taken by the Committee</td>
<td>-</td>
<td>Governments</td>
<td>Appendix VIII</td>
</tr>
<tr>
<td>Risk Analysis</td>
<td>-</td>
<td>France Australia, Canada, the Netherlands, New Zealand, Norway, USA 10th CCRVDF</td>
<td>para. 14</td>
</tr>
<tr>
<td>Residues of Veterinary Drugs in Raw Milk and Milk Products</td>
<td>-</td>
<td>USA France, Switzerland, Thailand, UK 10th CCRVDF</td>
<td>para. 9</td>
</tr>
<tr>
<td>International Cooperation on the Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products</td>
<td>-</td>
<td>OIE</td>
<td>para. 22</td>
</tr>
<tr>
<td>Progress Report on Compendium of Veterinary Drugs</td>
<td>-</td>
<td>United States</td>
<td>paras. 63</td>
</tr>
</tbody>
</table>
LIST OF PARTICIPANTS
LISTE DES PARTICIPANTS
LISTA DE PARTICIPANTES

Chairman: Dr. Stephen Sundlof
President: Director
Presidente: Center for Veterinary Medicine
Food and Drug Administration
HFV-1, MPN-2, 7500 Standish Place
Rockville, MD 20855
U.S.A.
Tel: (301) 594-1740
Fax: (301) 594-1830

Assistant to the Chairman: Dr. Sharon R. Thompson
Adjoint du président: Special Assistant to the Director
Ayudante del presidente: Center for Veterinary Medicine
Food and Drug Administration
HFV-3, MPN-2, 7500 Standish Place
Rockville, MD 20855
U.S.A.
Tel: (301) 594-1798
Fax: (301) 594-1830

MEMBER COUNTRIES
PAYS MEMBRES
PAISES MIEMBROS

ARGENTINA
ARGENTINE

Mr. Jose D. Molina
Agricultural Attaché
Embassy of Argentina
1600 New Hampshire Ave, NW.
Washington, D.C. 20009
U.S.A.
Tel: (202) 939-6446
Fax: (202) 332-1324

The heads of delegations are listed first; alternates, adviser and consultants are listed in alphabetical order.
Les chefs de délégation figurent en tête et les suppléants, conseillers et consultants sont énumérés par ordre alphabétique.
Figuran en primer lugar los Jefes de las delegaciones; los Suplentes, Asesores y Consultores aparecen por orden alfabético.
AUSTRALIA
AUSTRALIE
Dr. James (Jack) Y. Haslam
Veterinary Counsellor
Australian Embassy
1601 Massachusetts Ave., NW.
Washington, DC 20036
U.S.A.
Tel: (202) 797-3319
Fax: (202) 797-3037

Mr. Claude A. Gauchat
Executive Director
Avacare Limited
Locked Bag 916
North Sydney
Australia
Tel: (2) 992-22199
Fax: (2) 995-40588

Dr. Warren J. Henry
Director
AGAL Victoria
51-65 Clarke Street
South Melbourne 3205
Australia
Tel: (3) 968-51777
Fax: (3) 968-51788

Mr. Kerryn McDougall
Special Chemist
Chemical Residue Laboratories
NSW Agriculture
P.O. Box 285 Lismore
NSW Australia 2480
Tel: (66) 212-632
Fax: (66) 214-319

Dr. John Owusu
Manager, Development Projects and
International
National Registration Authority
P.O. Box 240
Queen Victoria Terrace
Barton ACT 2600
Australia
Tel: (6) 271-6375
Fax: (6) 272-4783

Dr. Jonathan J. Webber
Manager, Animal Programs
National Residue Survey
P.O. Box E11
Queen Victoria Terrace
Canberra ACT 2600
Australia
Tel: (6) 272-3762
Fax: (6) 272-4023

BELGIUM
BELGIQUE
BELGICA
Dr. Marc Cornelis
Inspecteur - Expert
Ministère de la Santé Publique
Institut d’Expertise Vétérinaire
Rue de la Loi, 56
1040 Brussels
Belgium
Tel: (2) 287-0253
Fax: (2) 287-0200

Dr. Leo Van Leemput
AGIM/AVGI
Turnhoutseweg 30
B-2340 Beerse
Belgium
Tel: (14) 602176
Fax: (14) 603777

BOTSWANA
Dr. Kereng Masupu
Deputy Director
Department of Animal Health and Production
Private Bag 0032
Gaborone, Botswana

Ms. Seinwaeng Kagfela
Chemist
Department of Animal Health and Production
Private Bag 0032
Gaborone, Botswana

Ms. Jennifer Morongoe Rathebe
Quality Assurance Laboratory Manager
Botswana Meat Commission
Private Bag 4
Lobatse, Botswana
BRAZIL
BRESIL
BRASIL

Mr. Adauto L. Rodrigues
Coordenador Para Assuntos do Codex/MAARA
Ministry of Agriculture
Brasilia CEP: 70.043.900
Brazil
Tel: (61) 218-2314
Fax: (61) 224-3995

Dr. Nelson Antunes
President
Sindan, Sindicato Nacional Da Industria de Defensivos Animals
Rua Muniz De Souta 1,304
01534-001- Sao Paulo-SP
Brazil
Tel: (011) 270-4633
Fax: (011) 279-5482

Mr. Francisco Bezerra da Silva
Ministerio du Agricultura
Brasilia 1DF
CEP 70043.900 Brazil
Tel: (061) 226-9771/6182
Fax: (061) 218-2316

Mr. Manuel Montenegro
Head of Science and Technology Section
Brazilian Embassy
3006 Massachusetts Ave. NW
Washington, D.C. 20008
U.S.A.
Tel: (202) 745-2750
Fax: (202) 745-2827

Dr. Joao Palermo-Neto
Department of Pharmacology and Toxicology
University of Sao Paulo
Av. Corifeu Azevedo Marques, 2720
CEP 05340-900 Sao Paulo
Brazil
Tel: (011) 818-7685
Fax: (011) 818-7829

Ms. Maria A. Ribeiro Oliveira
Chief, Division of Veterinary Products
Department of Animal Health
Ministry of Agriculture
Brasilia 1DF, Brazil
CEP 70043.900
Tel: (061) 223-7073
Fax: (061) 226-3446

CANADA

Dr. Tim Scott
Director
Bureau of Veterinary Drugs
Health Canada
Room 2605-C, Main Statistics Canada Bldg.
Postal Locator 0302 H3
Tunney's Pasture, Ontario K1AOL2
Canada
Tel: (613) 957-3824
Fax: (613) 957-3851

Dr. Paul Dick
Manager, Research & Development
Elanco Canada
Canadian Animal Health Institute
27 Cork Street West
Guelph, Ontario NIH 2W9
Canada
Tel: (519) 763-7777
Fax: (519) 763-7407

Dr. James D. MacNeil
Head, Food Animal Chemical Residues
Health of Animals Laboratory
Agriculture and Agri-Food Canada
116 Veterinary Road
Saskatoon, Saskatchewan
S7N 2R3 Canada
Tel: (306) 975-5347
Fax: (306) 975-5711

Dr. Man Sen Yong
Bureau of Veterinary Drugs
Food Directorate
Health Protection Branch
Health Canada, Main Statistics Building
Tunney's Pasture, Locator # 0302H3
Ottawa, Ontario KIA OL2
Canada
Tel: (613) 957-3857
Fax: (613) 957-3861
Mr. Milter Green Lauridsen  
Senior Chemist  
National Food Agency  
Morkhoj Bygade 19  
DK-2860 Soborg  
Denmark  
Tel: (39) 69-66-00  
Fax: (39) 66-01-00

Ms. Gitte Rasmussen  
Scientific Advisor  
National Food Agency  
Moerkhoj Bygade 19  
2860 Soborg  
Denmark  
Tel: (39) 69-6600  
Fax: (39) 66-0100

Mr. Torben Westfahl  
Master of Science  
Danish Veterinary Service  
Odisvej 4, Postboks 93  
DK-4100 Ringsted  
Denmark  
Tel: (53) 618061  
Fax: (53) 619048

EGYPT  
EGYPTE  
EGIPTO

Prof. Dr. Moustafa M. Heikal  
Director General  
Organization for Veterinary Services  
1-Nadi El Seid Street  
Dokki-Giza  
Egypt  
Tel: (2) 348-1763  
Fax: (2) 348-1763

Dr. Ibrahim A. El-Eidy  
Animal Health Research Institute  
Dokki-Cairo  
Egypt

FINLAND  
FINLANDE  
FINLANDIA

Dr. Jorma Hirn  
National Veterinary and Food Research Institute  
P.O. Box 368  
SF-00231 Helsinki  
Finland  
Tel: (0) 393-1841  
Fax: (0) 393-1907

Ms. Erja Lindfors  
National Veterinary and Food Research Institute  
P.O. Box 368  
SF-00231 Helsinki  
Finland  
Tel: (0) 393101  
Fax: (0) 3931920

FRANCE  
FRANCIA

Mr. Jacques Boisseau  
Ministère de l’Agriculture et de la Forêt  
CNEVA  
Agence Nationale du Médicament Vétérinaire  
La Haute-Marche  
Javene 35133 Fougères  
France  
Tel: (9) 994-7872  
Fax: (9) 994-7899

Mr. Jean-Pierre Doussin  
Vice-Président du Comité National du Codex Alimentarius  
Direction Générale de la Concurrence, de la Consommation et de la Repression des Fraudes  
59 boulevard Vincent Auriol  
75703 Paris Cedex 13  
France  
Tel: (1) 4497-3470  
Fax: (1) 4497-3037

Mr. Jean-Marc Heintz  
Nestlé France  
17-19 quai du Président Paul Doumer  
92414 Courbevoie Cedex  
France  
Tel: (1) 4904-2078  
Fax: (1) 4904-2938
Mr. Gilles Lelard  
Direction Générale de l'Alimentation  
Ministère de l'Agriculture  
175 rue du Chevaleret  
75648 Paris Cedex 13  
France  
Tel: 4955-8466

Mr. Georges Monsallier  
Rhône Mérieux  
BP 7123  
69348 Lyon Cedex 07  
France  
Tel: 7272-3176  
Fax: 7272-3211

GABON

Jean Pierre Ngoua  
Secrétaire Principal, Chargé du Comité National du Codex Alimentarius  
Commission Nationale de la FAO  
B.P. 551 Libreville  
Gabon

GERMANY  
ALLEMAGNE  
ALEMANIA

Prof. Dr. Reinhard Kroker  
Director  
Federal Institute for Health Protection of Consumers and Veterinary Medicine  
Diedersdorfer Weg 1  
D-12277 Berlin  
Germany  
Tel: (30) 8412-2364  
Fax: (30) 8412-2955/2965

Dr. Alexander Boettner  
Hoechst Veterinar GmbH  
Rheingausstrasse 190  
D-65203 Wiesbaden  
Germany  
Tel: (611) 962-7867  
Fax: (611) 962-7854

Dr. Klaus Koenig  
MSD Sharp & Dohme  
MSD AGVET  
Lindenplatz 1  
D-85540 Haar  
Germany  
Tel: (89) 456-11452  
Fax: (89) 456-11493

Dr. Udo Mallick  
Federal Institute for Health Protection of Consumers and Veterinary Medicine  
Diedersdorfer Weg 1  
D-12277 Berlin  
Germany  
Tel: (30) 8412-2381  
Fax: (30) 8412-2955

Dr. Martin Schneidereit  
Federal Association for Animal Health  
Aennchenplatz 6  
53173 Bonn  
Germany  
Tel: (228) 318296  
Fax: (228) 318298

INDONESIA  
INDONESIE

Mr. T.A.R. Hanafiah  
Head, Accreditation Division  
Center for Standardisation and Accreditation Agency for Agribusiness  
Ministry of Agriculture  
Talan Harsono Rm. # 3 Gdg A, lt. Z.  
Ragunan, Jukarta Selatan  
Indonesia  
Tel: (21) 780.4367  
Fax: (21) 780.4367

Mr. Benny Bahahadewa  
Second Secretary to the Economic Affairs Division  
Indonesian Embassy  
2020 Massachusetts Ave., N.W.  
Washington, D.C. 20036  
Tel: (202) 775-5241  
Fax: (202) 775-5365
Dr. Tri Satya N. Hutabarat
Head, Animal Product Safety Sub Directorate
Directorate General of Livestock Services
Ministry of Agriculture
Jalan Salemba Raya, 16
Jakarta, Indonesia
Tel: (21) 314.2979
Fax: (21) 314.2830

Mr. P. Natigor Siagian
Agricultural Attaché
Indonesian Embassy
2020 Massachusetts Ave., N.W.
Washington, D.C. 20036
U.S.A.
Tel: (202) 775-5340
Fax: (202) 775-5365

IRELAND
IRLANDE
IRLANDA

Dr. James W. Egan
Supt. Veterinary Inspector
Department of Agriculture, Food and Forestry
Kildare Street
Dublin 2, Ireland
Tel: (1) 607-2456
Fax: (1) 661-6263

Dr. Cyril O'Sullivan
Deputy Director (Veterinary)
National Drugs Advisory Board
Charles Lucas House
63-H, Adelaide Road
Dublin 2 Ireland
Tel: (1) 676-4971
Fax: (1) 676-4836

ISRAEL

Dr. Stefan Soback
Head, National Residue Control Laboratory
Ministry of Agriculture
Kimron Veterinary Institute
P.O. Box 12
50250 Beit Dagan
Israel
Tel: (3) 968-1713
Fax: (3) 968-1753
Dr. Takeshi Morita  
Section Chief  
Veterinary Sanitation Division  
Ministry of Health and Welfare  
1-2-2 Kasumigaseki, Chiyoda-ku  
Tokyo, Japan  
Tel: (3) 3503-1711 ext. 2439  
Fax: (3) 3503-7964

Dr. Hiroshi Tachi  
Technical Adviser  
Japan Veterinary Pharmaceutical Association  
Baji-Chikusan-Kaikan Bild.  
1-2 Kanda Surugadai, Chiyoda-ku  
Tokyo 101, Japan  
Tel: (3) 3294-3243  
Fax: (3) 3294-0084

Mr. Hideyuki Takuma  
Chief, Standards and Labelling Division  
Ministry of Agriculture, Forestry and Fisheries (MAFF)  
1-2-1 Kasumigaseki, Chiyoda-ku  
Tokyo, Japan  
Tel: (3) 3501-4094  
Fax: (3) 3502-0438

Mr. Hideki Tarumi  
First Secretary, Health and Welfare  
Embassy of Japan  
2520 Massachusetts Ave, N.W.  
Washington, D.C. 20008  
U.S.A.  
Tel: (202) 939-6723  
Fax: (202) 265-9473

Dr. Akio Tsuji  
Director  
Research Institute for Animal Science in Biochemistry and Toxicology  
3-7-11 Hashimotodal, Sagamihara-shi  
Kanagawa 229, Japan  
Tel: (427) 62-2775  
Fax: (427) 62-7979

Dr. Yoshitaka Yonehara  
Director  
Japan Veterinary Pharmaceutical Association  
Baji-Chikusan-Kaikan Bild.  
1-2 Kanda Surugadai, Chiyoda-ku  
Tokyo 101, Japan  
Tel: (3) 3294-3243  
Fax: (3) 3294-0084

Mr. Kaorhu Yoshmura  
Counselor  
Embassy of Japan  
2520 Massachusetts Ave. N.W.  
Washington, D.C. 20008  
U.S.A.  
Tel: (202) 939-6712  
Fax: (202) 265-9473

KENYA  
Dr. Julius K. Kajume  
Deputy Director of Veterinary Services  
Ministry of Agriculture, Livestock Development and Marketing  
P.O. Kabete  
Nairobi, Kenya  
Tel: 632231  
Fax: 631273

KOREA, REPUBLIC OF  
REPUBLICA DE COREA

Dr. Jong Myung Park  
Director, Pharmacology and Biochemistry Div.  
National Veterinary Research Institute  
Rural Development Administration  
#480, Anyang 6 Dong, Anyang City  
Gyunggi Do, 430-016  
Republic of Korea  
Tel: 343-67-1725  
Fax: 343-46-3511

Ki-Yoon Chang  
Veterinary Officer  
National Animal Quarantine Service  
Ministry of Agriculture, Forestry and Fisheries  
San 23-4 Deungchon-dong Kangseo-gu  
Seoul, Republic of Korea  
Tel: (2) 653.5038  
Fax: (2) 653.5039

Dr. Chung Won Euh  
Assistant Director, Animal Health Div.  
Ministry of Agriculture, Forestry & Fisheries  
#1, Choongang Dong, Kwachon City  
Gyunggi Do, 427-760  
Republic of Korea  
Tel: (2) 504-9438  
Fax: (2) 507-8966
Dr. Jong Min Jeon  
Veterinary Officer  
Technical Cooperation Division  
Ministry of Agriculture, Forestry & Fisheries  
#1, Choongang Dong, Kwachon City  
Gyunggi Do, 427-760  
Republic of Korea  
Tel: (2) 509-7294  
Fax: (2) 507-2095

Dr. Byoung Gon Jeong  
Veterinary Officer  
National Animal Quarantine Service  
Ministry of Agriculture, Forestry & Fisheries  
#SAN 23-4, Deungchon-Dong, Kangso-Ku  
Seoul City 157-030  
Republic of Korea  
Tel: 343-67-1725  
Fax: 343-46-8511

Dr. Kyun-teak Oh  
Deputy Director of Food Safety Division  
Ministry of Health and Welfare  
Government Bldg. No. 2  
Kwachon-City, Gyunggi-do  
Republic of Korea  
Tel: (2) 503-7586  
Fax: (2) 503-7534

Mr. On Han Shin  
Counselor for Health and Welfare  
Embassy of Korea  
2450 Massachusetts Ave, N.W.  
Washington, D.C. 20008  
U.S.A.  
Tel: (202) 939-5673  
Fax: (202) 387-0402

Dr. In-sang Song  
Director of Food Hygiene Research Department  
Korea Institute of Food Hygiene  
57-1 Noryangjin-dong, Dongjak-ku  
Seoul, Republic of Korea (156-050)  
Tel: (2) 824-8092  
Fax: (2) 824-1762

Mr. Jad El Hassan  
Counselor  
Embassy of Lebanon  
2560 28th St., NW  
Washington, D.C. 20008  
U.S.A.  
Tel: (202) 939-6305  
Fax: (202) 939-6324

Mr. Houssam A. Diab  
First Secretary  
Embassy of Lebanon  
2560 28th St., NW  
Washington, D.C. 20008  
U.S.A.  
Tel: (202) 939-6305  
Fax: (202) 939-6324

Mr. Biclair H.G. Andrianantoandro  
Economic and Commercial Counselor  
Embassy of Madagascar  
2374 Massachusetts Ave., NW.  
Washington, DC 20008  
U.S.A.  
Tel: (202) 265-5525  
Fax: (202) 265-3034

Ms. Akma Ngah Hamid  
Veterinary Public Health Laboratory  
Department of Veterinary Services  
Ministry of Agriculture  
46630 Petaling Jaya  
Selangor Darul & Ehsan  
Malaysia  
Tel: (3) 757-0960  
Fax: (3) 757-0973
MEXICO
MEXIQUE
Dr. Victoria Martha Chavez Nino
Subdirector of Industrial Services
Directorate of Animal Health
Secretary of Commerce
Cpl. Actipan del Valle
C.P. 03230 Mexico D.F.

MORROCCO
MAROC
MARRUECOS
Mr. Med Reda Benkhaldoun
Ministère de l'Agriculture
Direction de L'Elenage
Rabat, Morrocco
Tel: (212) 7764315
Fax: (212) 7764406

Mr. Mohamed Mostafa Bakkali
Director General of Bjopharma
Ministère de l'Agriculture
Route de Casablanca KM 2
Rabat BP4569, Morrocco
Tel: 212.7.691692/650454
Fax: 212.7.691689

THE NETHERLANDS
PAYS-BAS
PAISES BAJOS
Dr. Cornelia Loesberg
Ministry of Agriculture, Nature Management
and Fisheries
Head, Foodstuffs & Risk Management Division
P.O. Box 20401
2500 EK The Hague
The Netherlands
Tel: (70) 379-3429
Fax: (70) 347-7552

Mr. William F. Droppers, DVM
Ministry of Health, Welfare and Sports
Food and Product Safety Affairs
P.O. Box 3008
2280 MK Riijsijk (ZH)
The Netherlands
Tel: (70) 340-69999
Fax: (70) 340-5177

Mr. Jos H. Goebbels, DVM
Ministry of Health, Welfare and Sports
Veterinary Inspectorate
P.O. Box 5406
2280 HK Riijsijk
The Netherlands
Tel: (70) 340-7039
Fax: (70) 340-7080

Dr. Carla A. Rutgers
Ministry of Agriculture, Nature Management
and Fisheries
P.O. Box 20401
2500 EK The Hague
The Netherlands
Tel: (70) 379-3071
Fax: (70) 347-7552

Mr. William T. Jolly
National Manager, Residues
MAF Regulatory Authority
Ministry of Agriculture
P.O. Box 2526
Wellington, New Zealand
Tel: (4) 474-4156
Fax: (4) 474-4239
Dr. Nick C. Whelan
Registration Team Leader
Agricultural Compounds Unit
MAF, Regulatory Authority
Ward ST, Upper Hutt
New Zealand
Tel: (4) 528-0126
Fax: (4) 828-4675

NORWAY
NORVEGE
NORUEGA

Dr. John Race
International Liaison Officer
Norwegian Food Control Authority
P.O. Box 8187 DEP
0034 Oslo, Norway
Tel: 225-79900
Fax: 225-79901

Dr. Hilde Kruse
Department of Pharmacology, Microbiology and Food Hygiene
Norwegian College of Veterinary Medicine
P.O.B. 8146 Dep
N-0033 Oslo, Norway

Mr. Sverre O. Roald
Norwegian Government Fish Inspection
Quality Control Service
Directorate of Fisheries
P.O. Box 168
N-6001 Alesund, Norway
Tel: 701-27636
Fax: 701-29647

Prof. Magne Yndestad
Professor
Dept. of Pharmacology, Microbiology and Food Hygiene
Norwegian College of Veterinary Medicine
P.O. Box 8146 Dep.
N-0033 Oslo, Norway
Tel: 22-964830
Fax: 22-964850

PERU
PEROU
Sr. Gustavo Meza Cuadra
Economic Counsellor
Embassy of Peru
1700 Massachusetts Av.
Washington D.C. 20036
U.S.A.
Tel: 1 202 833-9860
Fax: 1 202 659-8124

PHILIPPINES
FILIPINAS
Victoriano B. Leviste
Agricultural Attaché
Embassy of the Philippines
1600 Massachusetts Avenue, NW.
Washington, DC 20036
U.S.A.
Tel: (202) 467-9422
Fax: (202) 467-9421

Mr. Sverre O. Roald
Norwegian Government Fish Inspection
Quality Control Service
Directorate of Fisheries
P.O. Box 168
N-6001 Alesund, Norway
Tel: 701-27636
Fax: 701-29647

Lucio C. Manghinang
Agricultural Analyst
Embassy of the Philippines
1600 Massachusetts Ave., NW
Washington, DC 20036
U.S.A.

POLAND
POLOGNE
POLONIA
Mr. Andrzej Ilczuk
Economic Attaché
Embassy of the Republic of Poland Economic Office
1503 21st Street, NW
Washington, DC 20036
U.S.A.
Tel: (202) 467-6690
Fax: (202) 833-8343
PORTUGAL

Dra Maria Helena Ponte
Instituto da Protecção da Produção
Agro-alimentar
Largo da Academia Nacional das Belas
Artes Nº2
Lisboa, Portugal
Tel: (1) 3465165
Fax: (1) 3463518

ROMANIA

Dr. L Teveloiu
Director of the Hygiene and Public Health Direction
National Sanitary Veterinary Agency
Ministry of Agriculture and Food
B-UL. Carol I Nr. 24 Sector III
Bucuresti Code 70033
Romania
Tel: 615-78-75

Mr. Dan V. Petrov
Director General
Romanian Standard Institute
13 J.L. Calderon
70201 Bucharest Section 2
Romania
Tel: (401) 312-6215
Fax: (401) 312-4744

Mrs. Olimpia Vorovenci
Romanian Standard Institute
13 J.L. Calderon
70201 Bucharest Section 2
Romania
Tel: (401) 312-6215
Fax: (401) 312-4744

SENEGAL

Prof. Francois A. Adebayo
Director, Science Agency
Veterinary Medicine
Senegal

Mr. Diakhaidia Diarra
National Codex Committee/SANAS
Senegal

SLOVAKIA

Dr. Ladislav Sovik
Institute of State Control for Veterinary Residues
Slovak Republic
Ms. Judita Hederova
Institute of State Control for Veterinary Residues
Slovak Republic

SPAIN

Dr. Odon Sobrino
Chief of Registration Service of Veterinary Drugs
Ministry of Agriculture
Velaquez 147
28071 Madrid, Spain
Tel: (1) 347-8339
Fax: (1) 347-8341

Dr. Jose A. Garrido
Ministry of Health and Consumer Protection
Paseo del Prado 18-20
28071 Madrid, Spain
Tel: (1) 596-2095
Fax: (1) 596-4409

SOUTH AFRICA

Dr. A. Pretorius
Dept. of Agriculture
Veterinary Public Health
Private Bag x138
Pretoria
Republic of South Africa
Tel: (12) 319-7523

SLOMANIA

SLOVAQUIE
ESLOVAQUIA

SOUTH AFRICA

AFRIQUE DU SUD
AFRICA DEL SUR

SPAIN

ESPAGNE
ESPAÑA

SOUTH AFRICA

AFRIQUE DU SUD
AFRICA DEL SUR

SPAIN

ESPAGNE
ESPAÑA
Mr. Jesus L. Miranda  
Counselor for Agriculture, Fisheries and Food  
Embassy of Spain  
2375 Pennsylvania Ave. NW  
Washington, D.C. 20037  
U.S.A.  
Tel: (202) 728-2339  
Fax: (202) 728-2320

Mr. Antonio Novas  
Attaché  
Embassy of Spain  
2375 Pennsylvania Ave. NW  
Washington, D.C. 20037  
U.S.A.  
Tel: (202) 728-2339  
Fax: (202) 728-2320

SWEDEN  
SUEDE  
SUECIA

Dr. Anders P. Manestam  
Chief Government Veterinary Inspector  
National Food Administration  
Box 622  
S-751 26 Uppsala  
Sweden  
Tel: (18) 175-737  
Fax: (18) 105-848

Dr. Hakan Johnsson  
Head of Chemistry Division 3  
National Food Administration  
Box 622  
S-751 26 Uppsala  
Sweden  
Tel: (18) 175-705  
Fax: (18) 105-848

SWITZERLAND  
SUISSE  
SUIZA

Dr. Herbert Koch  
Federal Veterinary Office  
Schwarzenburgstrasse 161  
CH-3097 Liebefeld-Ern  
Switzerland  
Tel: (31) 323-8539  
Fax: (31) 323-8522

Dr. Roland L. Dousse  
MIGROS - Genossenschaft-Bund  
Route de l'Industrie  
A784 Courtepin  
Switzerland  
Tel: (37) 34-3333  
Fax: (37) 34-2314

Dr. Josef R. Schlatter  
Federal Office of Public Health  
c/o Institute of Veterinary Pharmacology and Toxicology  
of Winterthurerstrasse 260  
CH-8057 Zuerich  
Switzerland  
Tel: (1) 257-6105  
Fax: (1) 257-6107

Dr. Jean A. Vignal  
Nestec Ltd.  
Avenue Henri Nestle, 55  
CH-1800 Vevey  
Switzerland  
Tel: (21) 924-3501  
Fax: (21) 924-4547

THAILAND  
THAILANDE  
TAILANDIA

Yuantar Pruksaraj  
Department of Livestock Development  
Phayathai Rd., Bangkok 10400  
Thailand  
Tel: (2) 251.8206/(2) 251.5136  
Fax: (2) 251.1942

Ranee Kumton  
Chief Commodity Standards Sub-Division  
Office of National Codex Committee  
Thai Industrial Standards Institute  
Rama 6 Street, Bangkok 10400  
Thailand  
Tel: (2) 202.3438/(2) 246.1992.3  
Fax: (2) 248.2987

Boonpeng Santiwattanatam  
The Federation of Thai Industries  
313 Silom Road C.P. Tower 27th Floor  
Bangkok 10500, Thailand  
Tel: (2) 231.0550  
Fax: (2) 631.0944
Warunee Sensupa  
Food Control Division  
Food and Drug Administration  
Tivanond Road, Nonthaburi 11000  
Thailand  
Tel: (2) 5918460.2  
Fax: (2) 5918460.2/123

Dr. Janenuj Wongtavatchai  
Department of Livestock Development  
Ministry of Agriculture  
Prayathai Rd.  
Bangkok 10400,  
Thailand  
Tel: (2) 251.8206/(2) 251.1942  
Fax: (2) 251.8206/(2) 251.1942

TUNISIA  
TUNISIE  
TUNEZ

Dr. Hannachi Abdelhamid  
Inspecteur Général de la Santé Publique  
Direction de l'Hygiène et de la Protection de l'Environnement  
Ministère de la Santé Publique  
Tunis, Tunisia  
Tel: 792887.801241

Dr. Hannachi Abdelhamid  
Inspecteur Général  
Direction de l'Hygiène du Milieu et de la Protection de l'Environnement  
Ministère de la Santé Publique  
Tunis, Tunisia  
Tel: 216 1 972-877  
Fax: 216 1 801-241

UNITED KINGDOM  
ROYAUME-UNI  
REINO UNIDO

Dr. K.N. Woodward  
Director of Licensing  
Veterinary Medicines Directorate  
Woodham Lane  
New Haw, Addlestone  
Surrey KT15 3NB  
United Kingdom  
Tel: 01932.336911  
Fax: 01932.336618

Mr. Roger Cook  
National Office of Animal Health Limited  
3 Crossfield Chambers  
Gladbeck Way, Enfield  
Middlesex EN2 7HF  
United Kingdom  
Tel: (0181) 367-3131  
Fax: (0181) 363-1155

Dr. Anthony J. Mudd  
Roche Products Ltd.  
Heanor Gate  
Heanor, Derbyshire DE75 7SG  
United Kingdom  
Tel: 01773 536610  
Fax: 01773 536585

Mr. Raj Patel  
Head of Analytical Chemistry Unit  
Veterinary Laboratories Agency  
Woodham Lane  
New Haw, Addlestone  
Surrey KT15 3NB  
United Kingdom  
Tel: 01932.357527  
Fax: 01932.357890

Dr. J.M. Rutter  
Chief Executive  
Veterinary Medicines Directorate  
Woodham Lane  
New Haw, Addlestone  
Surrey KT15 3NB  
United Kingdom  
Tel: 01932.336911  
Fax: 01932.336618

Dr. George Shearer  
Head Veterinary Drug Residues Section  
Central Science Laboratory  
Norwich Research Park  
Colney Lane  
Norwich NR4 7UQ  
United Kingdom  
Tel: 01603.259350  
Fax: 01603.501123
UNITED STATES OF AMERICA
ETATS-UNIS D'AMERIQUE
ESTADOS UNIDOS DE AMERICA

Dr. Marvin A. Norcross
U.S. Delegate
U.S. Coordinator for Codex Alimentarius
USDA, FSIS
Room 311, West End Court
1255 22nd Street, NW
Washington, D.C. 20250-3700
U.S.A.
Tel: (202) 254-2517
Fax: (202) 254-2530

Dr. Kenneth Aadsen
Inspection Services Division, FITS4
National Marine Fisheries Service
Room 6138
1335 East-West Highway
Silver Spring, MD 20910
U.S.A.
Tel: (301) 713-2355
Fax: (301) 713-1081

Mr. Jeffrey Brown
Executive Secretary
USDA, FSIS, Science and Technology
300 12th Street, SW, Room 409-Annex
Washington, DC 20250
U.S.A.
Tel: (202) 205-0081
Fax: (202) 205-0257

Dr. Richard Carnevale
Animal Health Institute
501 Wyeth St.
Alexandria, VA. 22314-1917
U.S.A.
Tel: (703) 684-0011
Fax: (703) 684-0125

Ms. Adrienne Dem
Editor
World Food Chemical News
1101 Pennsylvania Ave., SE
Washington, D.C. 20003
U.S.A.
Tel: (202) 544-1980
Fax: (202) 546-3890

Dr. Richard Ellis
Director, Chemistry Division
USDA, FSIS, Science and Technology
300 12th Street, SW, Room 603-Annex
Washington, DC 20250
U.S.A.
Tel: (202) 205-0623
Fax: (202) 205-0145

Dr. Gerald B. Guest
19105 Plummer Drive
Germantown, MD 20876
U.S.A.
Tel: (301) 972-1682
Fax: (301) 972-6690

Dr. Robert R. Jorgensen
Director, Governmental Relations Division
American Veterinary Medical Association
1101 Vermont Ave., N.W. Suite 710
Washington, D.C. 20005-3521
U.S.A.
Tel: (202) 789-0007
Fax: (202) 842-4360

Dr. Gordon Kemp
AHI Representative
Director of Science Policy Affairs
Pfizer, Inc.
Eastern Point Road
Groton, CT 06340
U.S.A.
Tel: (203) 441-4958, 1509
Fax: (203) 441-4101

Dr. David Kowalczyk
Monsanto Co., B25C
800 N. Lindbergh Blvd.
St. Louis, MO 63167
U.S.A.
Tel: (314) 694-5348
Fax: (314) 694-5271

Dr. Bruce Martin
Elanco Animal Health
2001 W. Main Street
P.O. Box 708
Greenfield, IN 46170
U.S.A.
Tel: (317) 277-5298
Fax: (317) 277-4755
Dr. Harless A. McDaniel  
American Veterinary Identification Devices  
15400 Aylesbury Street  
Silver Spring, MD  20905  
U.S.A  
Tel: (301) 384-1184  
Fax: (301) 384-1184  

Dr. Michael McGowan  
Director, Regulatory Affairs, AHPD  
Pfizer Inc.  
Eastern Point Road, Bldg. T201  
Groton, CT 06340  
U.S.A  
Tel: (860) 441-4947  
Fax: (860) 441-5779  

Mr. C.W. McMillan  
Consultant  
P.O. Box 10009  
Alexandria, VA  22310-0009  
U.S.A  
Tel: (703) 960-1982  
Fax: (703) 960-4976  

Dr. James Mock  
Hoffman-La-Roche, Inc.  
Animal Nutrition and Health  
22-10 Route 208 South  
Fairlawn, NJ  07410  
U.S.A  
Tel: (201) 703-2031  
Fax: (201) 794-7153  

Dr. Robert C. Livingston  
Alternate U.S. Delegate  
Director, Office of New Animal Drug Evaluation, HFV-100  
FDA, Center for Veterinary Medicine  
7500 Standish Place, Room 389  
Rockville, MD  20855  
U.S.A  
Tel: (301) 594-1620  
Fax: (301) 594-2297  

Dr. Richard Mikita  
USDA, FSIS, International Programs  
Room 341-E, Jamie L. Whitten Bldg.  
Washington, DC  20250-3700  
U.S.A.  
Tel: (202) 720-0290  
Fax: (202) 690-0766  

Ms. Joan Mondschein  
Confidential Assistant  
USDA/FSIS  
Room 1763, South Building  
14th & Independence Ave., SW  
Washington, DC  20250  
U.S.A.  
Tel: (202) 720-7323  
Fax: (202) 720-5124  

Dr. John O’Rangers  
Office of New Animal Drug Evaluation  
Center for Veterinary Medicine  
Food and Drug Administration  
7500 Standish Place, Room 389  
Rockville, MD  20855  
U.S.A  
Tel: (301) 594-1645  
Fax: (301) 594-2297  

Mr. Phillip C. Olsson, Esq.  
Olsson, Frank & Weeda, P.C.  
1400 Sixteenth Street, NW, Suite 400  
Washington, D.C.  20036  
U.S.A.  
Tel: (202) 789-1212  
Fax: (202) 234-3550  

Dr. Larry C. Pendulum  
Director, Regulatory Affairs  
Lilly Research Laboratories  
2001 W. Main Street  
P.O. Box 708  
Greenfield, IN  46140  
U.S.A.  
Tel: (317) 277-4466  
Fax: (317) 277-4962  

Dr. W. Martin Strauss  
Agricultural Regulation  
Director  
Monsanto Company  
700 14th St., NW, Ste. 1100  
Washington, D.C.  20005  
U.S.A.  
Tel: (202) 383-2859  
Fax: (202) 783-2468
Dr. J.R. Tomerlin
TAS Inc.
Director, Exposure Assessment
1000 Potomac St., NW
Washington, D.C. 20007
U.S.A.
Tel: (202) 337-2625
Fax: (202) 337-1744

Ms. Carolyn F. Wilson
International Trade Specialist
U.S. Department of Agriculture
FAS/ITP/OFSIS
Room 5545, South Building
14th & Independence Ave., SW
Washington, DC 20250
U.S.A.
Tel: (202) 720-2239
Fax: (202) 690-0677

URUGUAY
Mr. Renata Antonaz
Department of Residues
Veterinary Laboratories
Ministry of Agriculture, Cattle and Fisheries
Ruta 8 Brig. Juan Antonio Lavalleja Km 17500
Montevideo
Uruguay
Tel: (2) 22-1063
Fax: (2) 22-1157

OBSERVER COUNTRIES
PAYS OBSERVATEURS
PAISES OBSERVADORES

PUERTO RICO
PORTO RICO

Dr. Hernan Horta Cruz
Assistant Secretary of Health and Environmental Health
Department of Health
Call Box 70184
San Juan 00936
Puerto Rico
Tel: (809) 274-7796/7797
Fax: (809) 758-6285

INTERNATIONAL ORGANIZATIONS
ORGANISATIONS INTERNATIONALES
ORGANIZACIONES INTERNACIONALES

AOAC INTERNATIONAL (AOAC)
Mr. George Heavner
Technical Coordinator
AOAC International
481 North Frederick Ave.
Suite 500
Gaithersburg, MD
U.S.A.
Tel: (301) 924-7077
Fax: (301) 924-7089

Dr. Alexander MacDonald
AOAC Representative to CCRVDF
16 Cypress Avenue
N Caldwell, NJ 07006
U.S.A.
Tel: (201) 228-2392
Fax: (201) 228-3498

CONSUMERS INTERNATIONAL
Ms. Lisa Lefferts
6719 Chillum Manor Road
Hyattsville, MD 20783
U.S.A.
Tel: (301) 559-3630
Fax: (301) 853-3272

COUNCIL OF THE EUROPEAN UNION
CONSEIL DE L'UNION EUROPEENNE
CONSEJO DE L'UNION EUROPEA

Mr. Paul Culley
Council of the European Union
Secretariat
175 Rue de la Loi
1048 Brussels, Belgium
Tel: (2) 285-6197
Fax: (2) 285-7686
EUROPEAN COMMISSION
COMMISSION EUROPEENNE
COMISION EUROPEA
Dr. Barbara Roestel-Peters
Directorate General Industry
European Commission
Rue de La Loi 200
1049 Brussels, Belgium
Tel: (2) 296-1804
Fax: (2) 296-1520

Dr. Claire Gaudot
Administrateur Principal
Directorate General Agriculture
European Commission
86 Rue de la Loi 7/36
1049 Brussels, Belgium
Tel: (2) 295-6216
Fax: (2) 295-3144

INTERNATIONAL DAIRY FEDERATION (IDF)
FEDERATION INTERNATIONALE DE LAITERIE (FIL)
FEDERACION INTERNACIONAL DE LECHERIA (FIL)
Prof. Dr. W. Heeschen
Federal Agency for Milk Research
Institute of Hygiene
Postfach 6069
D-24121 Kiel
Germany
Tel: (431) 609.392
Fax: (431) 609.222

OFFICE INTERNATIONAL DES EPIZOOTICS (OIE)
OFFICE INTERNATIONNEL DES EPIZOOTIES
OFICINA INTERNACIONAL DE EPIZOOTIAS
Mr. Jacques Boisseau
Directeur du Laboratoire National des Medicaments Veterinaires
Javene
35133 Fougères
France

PAN AMERICAN HEALTH ORGANIZATION (PAHO)
Dr. Claudio R. Almeida
Regional Advisor for Food Protection
Pan American Health Organization
525 Twenty-Third Street, N.W.
Washington, DC 20037-2895
U.S.A.
Tel: (202) 861-3193
Fax: (202) 861-8488

WORLDWIDE COUNCIL OF THE ANIMAL HEALTH INDUSTRY CONSULTATION MONDIALE DE L'INDUSTRIE DE LA SANTE ANIMALE (COMISA)
Dr. Christian Verschueren
Secretary General, COMISA
Rue Defacqz 1
1050 Brussels, Belgium
Tel: (2) 537-1182
Fax: (2) 537-0049

Dr. Peter H. Altreuther
President, COMISA
c/o Bayer-AG
Animal Health Division
D-51368 Leverkusen
Germany
Tel: (217) 338-4174
Fax: (217) 338-4896

Dr. Raul J. Guerrero
FILASA/COMISA
SR Clinical Research Project
Veterinarian
Lilly Research Laboratories
P.O. Box
Greenfield, Indiana 46140
U.S.A.
Tel: (317) 277-4434
Fax: (317) 277-4755

Dr. David Miller
TBCT/SANDOZ Pharmaceuticals
Frimley Business Park
Camberley, Surrey GU 5SG
United Kingdom
Tel: 1-276-25500
Fax: 1-276-27555
JOINT FAO/WHO SECRETARIAT
SECRETARIAT MIXTE FAO/OMS
SECRETARIA CONJUNTA FAO/OMS

Dr. Yukiko Yamada
Food Standards Officer
Joint FAO/WHO Food Standards Programme
FAO
Via delle Terme di Caracalla
00100 Rome, Italy
Tel: (6) 5225-5443
Fax: (6) 5225-4593

Mr. David Byron
Food Standards Officer
Joint FAO/WHO Food Standards Programme
FAO
Via delle Terme di Caracalla
00100 Rome, Italy
Tel: (6) 5225-4419
Fax: (6) 5225-4593

UNITED STATES SECRETARIAT
SECRETARIAT DES ETATS-UNIS
SECRETARIA DE LOS ESTADOS UNIDOS

Ms. Rhonda S. Nally
Executive Officer for Codex Alimentarius
USDA/FSIS/OA
West End Court, Room 311
Washington, DC 20250
U.S.A.
Tel: (202) 254-2517
Fax: (202) 254-2530

Mr. Craig T. Fedchock
Advisory Committee Specialist
USDA, FSIS, OA
Room 311 West End Court
1255 22nd Str., NW
Washington, D.C. 20250, U.S.A.
Tel: (202) 254-2517
Fax: (202) 254-2530

Ms. Edith E. Kennard
International Liaison Specialist
International Programs
FSIS, Suite 3700, Franklin Court
U.S. Department of Agriculture
Washington, D.C. 20250, U.S.A.
Tel: (202) 501-6022
Fax: (202) 501-6929
Ms. Margaret Klock  
Office of the Director  
Center for Veterinary Medicine (HFV-1)  
Food and Drug Administration  
7500 Standish Place  
Rockville, MD 20855, U.S.A.  
Tel: (301) 594-1740  
Fax: (301) 594-1830  

Ms. Patty L. Woodall  
Assistant for Codex Alimentarius  
Room 311, West End Court  
USDA, FSIS, OA  
Washington, D.C. 20250, U.S.A.  
Tel: (202) 254-2517  
Fax: (202) 254-2530  

Ms. Amelia White  
Management Analyst  
Room 309, Annex Building  
USDA/FSIS/S&T/MD  
300 12th Street, SW  
Washington, DC 20250  
U.S.A.  

Ms. Natalie Zalc  
Program Assistant  
USDA/FSIS/OA  
West End Court, Room 311  
Washington, DC 20250. U.S.A.  
Tel: (202) 254-2517  
Fax: (202) 254-2530  

SPECIAL  
ESPECIAL  

Lester M. Crawford, DVM, PhD  
Executive Director  
Association of American Veterinary Medical Colleges  
1101 Vermont Avenue, NW, Suite 710  
Washington, DC 20005-3521  
U.S.A.  

Ms. Danielle Schor  
USDA/FSIS/ILA  
Room 1175, South Building  
14th and Independence Ave., SW  
Washington, DC 20250, U.S.A.  
Tel: (202) 720-9113  

Mr. Michael Taylor  
Acting Under Secretary for Food Safety  
U.S. Department of Agriculture  
Room 331-E Jamie Whitten Bldg.  
Washington, D.C. 20250, U.S.A.  
Tel: (202) 720-7025  
Fax: (202) 690-4437  

Dr. Chandrall A. Weerasinghe  
Pfizer Inc., Central Research Division  
Eastern Point Road  
Groton, CT 06340, U.S.A  
Tel: (203) 441-8022  
Fax: (203) 441-5779  

Ms. Carmela Pengelly  
North American Editor  
Animal Pharm  
1775 Broadway, Suite 511  
New York, N.Y. 10019, U.S.A.  

Dr. Thomas G. Wilcox  
Food and Drug Administration  
200 C Street, S.W.  
Washington, D.C. 20204, U.S.A.  

Dr. Debra Street  
Epidemiology Branch, HFS-728  
Food and Drug Administration  
200 C Street, SW  
Washington, DC 20204, U.S.A.  
Tel: (202) 205-5329  

Dr. Pat McCarthy  
Staff Fellow  
Food and Drug Administration  
HFS-728, 200 C Street, SW  
Washington, DC 20204, U.S.A.  
Tel: (202) 205-5890
1. **Substance: Levamisole**

2. Acceptable Daily Intake (ADI) as established by JECFA

3.1 (a) Commodity: Liver (cattle, pigs, sheep)

(b) MRL: 100 µg/kg

(c) Definition of residue on which MRL was set: Levamisole

4. Reference to recommended method(s) of analysis


5. Reference to JECFA Reports:

   WHO TRS 799 (1990)
   WHO FAS 27 (1991)
   FAO FNP 41/3 (1991)
   WHO TRS 851 (1995)
   WHO FAS 33 (1994)
   FAO FNP 41/6 (1994)

6. Reference to previous Codex Reports:

   Appendix II, ALINORM 91/31A
   Appendix V, ALINORM 93/31A
   Appendix II, ALINORM 95/31
   Appendix V, ALINORM 95/31

---

1. **Substance: Triclabendazole**

2. Acceptable Daily Intake (ADI) as established by JECFA

3.1 (a) Commodity: Muscle (cattle)

(b) MRL: 200 µg/kg

(c) Definition of residue on which MRL was set: 5-Chloro-6-(2',3'-dichlorophenoxy)-benzimidazole-2-one

3.2 (a) Commodity: Liver and kidney (cattle)
33

(b) MRL: 300 µg/kg
(c) Definition of residue on which MRL was set: 5-Chloro-6-(2',3'-dichlorophenoxy)-benzimidazole-2-one

3.3 (a) Commodity: Muscle, liver and kidney (sheep)
(b) MRL: 100 µg/kg
(c) Definition of residue on which MRL was set: 5-Chloro-6-(2',3'-dichlorophenoxy)-benzimidazole-2-one

4. Reference to recommended method(s) of analysis

5. Reference to JECFA Reports:
WHO TRS 832 (1993)
WHO FAS 31 (1992)
FAO FNP 41/5 (1992)

6. Reference to previous Codex Reports:
Appendix IV, ALINORM 93/31A
Appendix III, ALINORM 95/31
DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(Retained at Step 7 of the Codex Procedure)

NOTE: Section 5 - Reference to JECFA Reports - contains references to the reports of meetings of the Joint FAO/WHO Expert Committee on Food Additives, as published in the WHO Technical Report Series (TRS). Relevant toxicological monographs are published in the WHO Food Additives Series (FAS) and residue monographs of the substances concerned are published in the FAO Food and Nutrition Paper (FNP) Series.

1. **Substance: Diminazene**

2. Acceptable Daily Intake (ADI) as established by JECFA
   0-100 µg/kg body weight

3.1 (a) Commodity: (a) Muscle (cattle)
   (b) MRL: (b) 500 µg/kg
   (c) Definition of residue on which MRL was set: (c) Diminazene

3.2 (a) Commodity: (a) Liver (cattle)
   (b) MRL: (b) 12000 µg/kg
   (c) Definition of residue on which MRL was set: (c) Diminazene

3.3 (a) Commodity: (a) Kidney (cattle)
   (b) MRL: (b) 6000 µg/kg
   (c) Definition of residue on which MRL was set: (c) Diminazene

3.4 (a) Commodity: (a) Milk (cattle)
   (b) MRL: (b) 150 µg/l (Limit of quantitation of the analytical method)
   (c) Definition of residue on which MRL was set: (c) Diminazene

4. Reference to recommended method(s) of analysis

5. Reference to JECFA Reports:
   - WHO TRS 788 (1989)
   - WHO FAS 25 (1990)
   - FAO FNP 41/2 (1990)
   - WHO TRS 851 (1995)
   - WHO FAS 33 (1994)
   - FAO FNP 41/6 (1994)

6. Reference to previous Codex Reports:
   Appendix IV, ALINORM 95/31

1. **Substance: Levamisole**

2. Acceptable Daily Intake (ADI) as established by JECFA
   0-6 µg/kg body weight
3.1 (a) Commodity: (a) Muscle, kidney and fat (cattle, pigs, sheep, poultry)
(b) MRL: (b) 10 µg/kg
(c) Definition of residue on which MRL was set: (c) Levamisole

3.2 (a) Commodity: (a) Liver (poultry)
(b) MRL: (b) 100 µg/kg
(c) Definition of residue on which MRL was set: (c) Levamisole

4. Reference to recommended method(s) of analysis

5. Reference to JECFA Reports: WHO TRS 799 (1990)
WHO FAS 27 (1991)
FAO FNP 41/3 (1991)
WHO TRS 851 (1995)
WHO FAS 33 (1994)
FAO FNP 41/6 (1994)

6. Reference to previous Codex Reports: Appendix II, ALINORM 91/31A
Appendix V, ALINORM 93/31A
Appendix II, ALINORM 95/31

1. Substance: Triclabendazole
2 Acceptable Daily Intake (ADI) as established by JECFA
0.3 µg/kg body weight

3.1 (a) Commodity: (a) Fat (cattle, sheep)
(b) MRL: (b) 100 µg/kg
(c) Definition of residue on which MRL was set: (c) 5-Chloro-6-(2',3'-dichlorophenoxy)benzimidazole-2-

4. Reference to recommended method(s) of analysis

5. Reference to JECFA Reports: WHO TRS 832(1993)
WHO FAS 31 (1992)
FAO FNP 41/5 (1992)

6. Reference to previous Codex Reports: Appendix IV, ALINORM 93/31A
Appendix III, ALINORM 95/31
NOTE: Section 5 - Reference to JECFA Reports - contains references to the reports of meetings of the Joint FAO/WHO Expert Committee on Food Additives, as published in the WHO Technical Report Series (TRS). Relevant toxicological monographs are published in the WHO Food Additives Series (FAS) and residue monographs of the substances concerned are published in the FAO Food and Nutrition Paper (FNP) Series.

1. Substance: Carazolol

2. Acceptable Daily Intake (ADI) as established by JECFA

3.1 (a) Commodity: (a) Muscle and fat/skin (pigs)
(b) MRL: (b) 5 µg/kg (The concentration at the injection site may exceed the ADI.)
(c) Definition of residue on which MRL was set: (c) Carazolol

3.2 (a) Commodity: (a) Liver and kidney (pigs)
(b) MRL: (b) 25 µg/kg (The concentration at the injection site may exceed the ADI.)
(c) Definition of residue on which MRL was set: (c) Carazolol

4. Reference to recommended method(s) of analysis


5. Reference to JECFA Reports:

WHO TRS 815 (1991)
WHO FAS 29 (1991)
1. Substance: Ceftiofur sodium

2. Acceptable Daily Intake (ADI) as established by JECFA

3.1 (a) Commodity: Muscle (cattle & pigs)
(b) MRL: 200 µg/kg
(c) Definition of residue on which MRL was set: Desfuroylceftiofur

3.2 (a) Commodity: Liver (cattle & pigs)
(b) MRL: 2000 µg/kg
(c) Definition of residue on which MRL was set: Desfuroylceftiofur

3.3 (a) Commodity: Kidney (cattle & pigs)
(b) MRL: 4000 µg/kg
(c) Definition of residue on which MRL was set: Desfuroylceftiofur

3.4 (a) Commodity: Fat (cattle & pigs)
(b) MRL: 600 µg/kg
(c) Definition of residue on which MRL was set: Desfuroylceftiofur

3.5 (a) Commodity: Milk (cattle)
(b) MRL: 10 µg/l
(c) Definition of residue on which MRL was set: Desfuroylceftiofur

4. Reference to recommended method(s) of analysis

5. Reference to JECFA Reports:
WHO TRS in preparation
WHO FAS 35 in preparation
FAO FNP 41/8 in preparation

6. Reference to previous Codex Reports:
Appendix V, ALINORM 93/31A
Appendix V, ALINORM 95/31

1. Substance: Doramectin

2. Acceptable Daily Intake (ADI) as established by JECFA

3.1 (a) Commodity: Muscle (cattle)
(b) MRL: 0.5 µg/kg body weight
(c) Definition of residue on which MRL was set: None

3.2 (a) Commodity: Fat (cattle & pigs)
(b) MRL: 10 µg/kg (High concentration of residues at...
(c) Definition of residue on which MRL was set:

3.2 (a) Commodity: (a) Liver (cattle)
(b) MRL:
(b) 100 µg/kg (High concentration of residues at the injection site during the 35 day period after parenteral administration of the recommended dose.)

(c) Definition of residue on which MRL was set:

3.3 (a) Commodity: (a) Kidney (cattle)
(b) MRL:
(b) 30 µg/kg (High concentration of residues at the injection site during the 35 day period after parenteral administration of the recommended dose.)

(c) Definition of residue on which MRL was set:

3.4 (a) Commodity: (a) Fat (cattle)
(b) MRL:
(b) 150 µg/kg (High concentration of residues at the injection site during the 35 day period after parenteral administration of the recommended dose.)

4. Reference to recommended method(s) of analysis

5. Reference to JECFA Reports:
   WHO TRS in preparation
   WHO FAS 35 in preparation
   FAO FNP 41/8 in preparation

6. Reference to previous Codex Reports:
   None

1. Substance: Moxidectin

2. Acceptable Daily Intake (ADI) as established by JECFA
   0.2 µg/kg body weight

3.1 (a) Commodity: (a) Muscle (cattle, sheep)
(b) MRL:
(b) 20 µg/kg (The high concentrations and great variation in the level of residues at the injection site over a 49-day period after dosing cattle.)

(c) Definition of residue on which MRL was set:

3.2 (a) Commodity: (a) Liver (cattle, sheep)
3.3 (a) Commodity: MRL:

(c) Definition of residue on which MRL was set:

3.4 (a) Commodity:

(b) MRL:

(c) Definition of residue on which MRL was set:

4. Reference to recommended method(s) of analysis

5. Reference to JECFA Reports:

6. Reference to previous Codex Reports:

None

1. Substance: Spiramycin

2. Acceptable Daily Intake (ADI) as established by JECFA:

(b) 0-50 μg/kg body weight

3.1 (a) Commodity:

(b) MRL:

(c) Definition of residue on which MRL was set:

3.2 (a) Commodity:

(b) MRL:

(c) Definition of residue on which MRL was set:

3.3 (a) Commodity:

(b) MRL:

(c) Definition of residue on which MRL was set:

3.4 (a) Commodity:

(c) Moxidectin

(a) Kidney (cattle, sheep)

(b) 50 μg/kg (The high concentrations and great variation in the level of residues at the injection site over a 49-day period after dosing cattle.)

(c) Moxidectin

(a) Fat (cattle, sheep)

(b) 500 μg/kg (The high concentrations and great variation in the level of residues at the injection site over a 49-day period after dosing cattle.)

(c) Moxidectin

(a) Muscle (cattle)

(b) 100 μg/kg

(c) Sum of spiramycin and neospiramycin

(a) Muscle (pigs)

(b) 200 μg/kg

(c) Total antimicrobially-active residues expressed as spiramycin equivalents

(a) Muscle (chickens)

(b) 200 μg/kg

(c) Sum of spiramycin and neospiramycin

(a) Liver (cattle)
3.5 (a) Commodity: Liver (chickens)  
(b) MRL: 300 μg/kg  
(c) Definition of residue on which MRL was set: Sum of spiramycin and neospiramycin

3.6 (a) Commodity: Kidney (cattle)  
(b) MRL: 200 μg/kg  
(c) Definition of residue on which MRL was set: Sum of spiramycin and neospiramycin

3.7 (a) Commodity: Kidney (chickens)  
(b) MRL: 800 μg/kg  
(c) Definition of residue on which MRL was set: Sum of spiramycin and neospiramycin

3.8 (a) Commodity: Fat (cattle, chickens)  
(b) MRL: 300 μg/kg  
(c) Definition of residue on which MRL was set: Sum of spiramycin and neospiramycin

4. Reference to recommended method(s) of analysis  
Weil, A., Rhone Merieux, Toulouse, France (muscle, liver, kidney, fat/cattle, poultry)

5. Reference to JECFA Reports:  
WHO TRS 815 (1991)  
WHO FAS 29 (1991)  
FAO FNP 41/4 (1991)  
WHO TRS 855 (1995)  
WHO FAS 34 (1995)  
FAO FNP 41/7 (1995)

6. Reference to previous Codex Reports:  
Appendix V, ALINORM 93/31  
Appendix V, ALINORM 93/31A  
Appendix V, ALINORM 95/31
NOTE: Section 5 - Reference to JECFA Reports - contains references to the reports of meetings of the Joint FAO/WHO Expert Committee on Food Additives, as published in the WHO Technical Report Series (TRS). Relevant toxicological monographs are published in the WHO Food Additives Series (FAS) and residue monographs of the substances concerned are published in the FAO Food and Nutrition Paper (FNP) Series.

1. Substance: Azaperone

2. Acceptable Daily Intake (ADI) as established by JECFA

   0-3 μg/kg body weight (Temporary)

3.1 (a) Commodity:

   (a) Muscle and fat (pigs)

3.2 (a) Commodity:

   (a) Liver and kidney (pigs)

3.1 (b) MRL:

   (b) 60 μg/kg (Temporary) (MRL is temporary because of the temporary ADI)

3.2 (b) MRL:

   (b) 100 μg/kg (Temporary) (MRL is temporary because of the temporary ADI)

(c) Definition of residue on which MRL was set:

   (c) Sum of azaperone and azaperol

4. Reference to recommended method(s) of analysis


5. Reference to JECFA Reports:

   WHO TRS 815 (1991)
   WHO FAS 29 (1991)
   FAO FNP 41/4 (1991)
   WHO TRS 855 (1995)
   WHO FAS 34 (1995)
   FAO FNP 41/7 (1995)

6. Reference to previous Codex Reports:

   None

1. Substance: Chlortetracycline and tetracycline

2. Acceptable Daily Intake (ADI) as established by JECFA

   0-3 μg/kg body weight (Group ADI for chlortetracycline, oxytetracycline and tetracycline)
### 1. Substance: Dexamethasone

2. Acceptable Daily Intake (ADI) as established by JECFA

<table>
<thead>
<tr>
<th>Substance</th>
<th>Commodity</th>
<th>MRL</th>
<th>Definition of residue on which MRL was set</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>Muscle and kidney (cattle, horses and pigs)</td>
<td>0.015 µg/kg body weight</td>
<td></td>
</tr>
</tbody>
</table>

#### 3.1 Commodity:
- (a) Muscle (cattle, pigs & poultry)
- (b) 100 µg/kg (Temporary)
- (c) Chlortetracycline & tetracycline

#### 3.2 Commodity:
- (a) Liver (cattle, pigs, sheep & poultry)
- (b) 300 µg/kg (Temporary)
- (c) Chlortetracycline & tetracycline

#### 3.3 Commodity:
- (a) Kidney (cattle, pigs, sheep & poultry)
- (b) 600 µg/kg (Temporary)
- (c) Chlortetracycline & tetracycline

#### 3.4 Commodity:
- (a) Eggs (poultry)
- (b) 200 µg/kg (Temporary)
- (c) Chlortetracycline & tetracycline

4. Reference to recommended method(s) of analysis

<table>
<thead>
<tr>
<th>Method</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AOAC 995.04 (milk/cattle) (provisional; 1995)</td>
<td></td>
</tr>
<tr>
<td>AOAC 995.09 (muscle, kidney/cattle, pigs, poultry) (provisional; 1995)</td>
<td></td>
</tr>
<tr>
<td>WHO TRS in preparation</td>
<td></td>
</tr>
<tr>
<td>WHO FAS 35 in preparation</td>
<td></td>
</tr>
<tr>
<td>FAO FNP 41/8 in preparation</td>
<td></td>
</tr>
</tbody>
</table>

5. Reference to JECFA Reports:

- WHO TRS in preparation
- WHO FAS 35 in preparation
- FAO FNP 41/8 in preparation

6. Reference to previous Codex Reports:

None

---

---
1. Substance: Diclazuril

2. Acceptable Daily Intake (ADI) as established by JECFA

3.1 (a) Commodity: Muscle (sheep, rabbits & poultry)
(b) MRL: 500 μg/kg (Temporary) (MRL is temporary because of the temporary ADI)
(c) Definition of residue on which MRL was set: Diclazuril

3.2 (a) Commodity: Liver (sheep, rabbits & poultry)
(b) MRL: 3000 μg/kg (Temporary) (MRL is temporary because of the temporary ADI)
(c) Definition of residue on which MRL was set: Diclazuril

3.3 (a) Commodity: Kidney (sheep, rabbits & poultry)
(b) MRL: 2000 μg/kg (Temporary) (MRL is temporary because of the temporary ADI)
(c) Definition of residue on which MRL was set: Diclazuril

3.4 (a) Commodity: Fat (sheep, rabbits & poultry)
(b) MRL: 1000 μg/kg (Temporary) (MRL is temporary because of the temporary ADI)
(c) Definition of residue on which MRL was set: Diclazuril

4. Reference to recommended method(s) of analysis

Van Leemput, L., Jannsen Pharmaceutical, Belgium (muscle, liver, kidney, fat/poultry, rabbits, sheep) (provisional; 1995)

5. Reference to JECFA Reports:

WHO TRS in preparation
WHO FAS 35 in preparation
FAO FNP 41/8 in preparation

6. Reference to previous Codex Reports:

Appendix V, ALINORM 95/31

1. Substance: Dihydrostreptomycin and streptomycin

2. Acceptable Daily Intake (ADI) as established by JECFA

3.1 (a) Commodity: Muscle, liver and fat (cattle, pigs, chickens &
3.2 (a) Commodity: Kidney (cattle, pigs, chickens and sheep)
(b) MRL: 1000 µg/kg (Temporary)
(c) Definition of residue on which MRL was set: Sum of dihydrostreptomycin and streptomycin

3.3 (a) Commodity: Milk (cattle)
(b) MRL: 200 µg/l (Temporary)
(c) Definition of residue on which MRL was set: Sum of dihydrostreptomycin and streptomycin

4. Reference to recommended method(s) of analysis

   WHO FAS 34 (1995)
   FAO FNP 41/7 (1995)

6. Reference to previous Codex Reports: None
1. **Substance:** Gentamicin

2. Acceptable Daily Intake (ADI) as established by JECFA: 0-4 μg/kg body weight (Temporary)

3.1 (a) Commodity: (b) MRL: (c) Definition of residue on which MRL was set:

- (a) Muscle & fat (cattle & pigs)
- (b) 100 μg/kg (Temporary)
- (c) Gentamicin

3.2 (a) Commodity: (b) MRL: (c) Definition of residue on which MRL was set:

- (a) Liver (cattle & pigs)
- (b) 200 μg/kg (Temporary)
- (c) Gentamicin

3.3 (a) Commodity: (b) MRL: (c) Definition of residue on which MRL was set:

- (a) Kidney (cattle & pigs)
- (b) 1000 μg/kg (Temporary)
- (c) Gentamicin

3.4 (a) Commodity: (b) MRL: (c) Definition of residue on which MRL was set:

- (a) Milk (cattle)
- (b) 100 μg/l (Temporary)
- (c) Gentamicin


5. Reference to JECFA Reports:

- WHO TRS 855 (1995)
- WHO FAS 34 (1995)
- FAO FNP 41/7 (1995)

6. Reference to previous Codex Reports: None

---

1. **Substance:** Moxidectin

2. Acceptable Daily Intake (ADI) as established by JECFA: 0-2 μg/kg body weight

3.1 (a) Commodity: (b) MRL: (c) Definition of residue on which MRL was set:

- (a) Muscle (deer)
- (b) 20 μg/kg (Temporary)
- (c) Moxidectin
3.2 (a) Commodity: Liver (deer)
(b) MRL: 100 µg/kg (Temporary)
(c) Definition of residue on which MRL was set:
(c) Moxidectin

3.3 (a) Commodity: Kidney (deer)
(b) MRL: 50 µg/kg (Temporary)
(c) Definition of residue on which MRL was set:
(c) Moxidectin

3.4 (a) Commodity: Fat (deer)
(b) MRL: 500 µg/kg (Temporary)
(c) Definition of residue on which MRL was set:
(c) Moxidectin

4. Reference to recommended method(s) of analysis
WHO TRS in preparation
WHO FAS 35 in preparation
FAO FNP 41/8 in preparation

5. Reference to JECFA Reports:

6. Reference to previous Codex Reports:
None

1. Substance: Neomycin

2 Acceptable Daily Intake (ADI) as established by JECFA
0-30 µg/kg body weight (Temporary)

3.1 (a) Commodity: Muscle, liver & fat (cattle, chickens, ducks, goats, pigs, sheep & turkeys)
(b) MRL: 500 µg/kg (Temporary)(MRL is temporary because of the temporary ADI.)
(c) Definition of residue on which MRL was set:
(c) Neomycin

3.2 (a) Commodity: Kidney (cattle, chickens, ducks, goats, pigs, sheep & turkeys)
(b) MRL: 5000 µg/kg (Temporary)(MRL is temporary because of the temporary ADI.)
(c) Definition of residue on which MRL was set:
(c) Neomycin

3.3 (a) Commodity: Eggs (chickens)
(b) MRL: 500 µg/kg (Temporary)(MRL is temporary because of the temporary ADI.)
(c) Definition of residue on which MRL was set:
(c) Neomycin

3.4 (a) Commodity: Milk (cattle)
(b) MRL: 500 µg/l (Temporary)(MRL is temporary because of the temporary ADI.)
1. **Substance: Spectinomycin**

2. Acceptable Daily Intake (ADI) as established by JECFA 0.40 µg/kg body weight

3.1 (a) Commodity: (a) Muscle (cattle, pigs & chickens)
(b) MRL: (b) 300 µg/kg (Temporary)
(c) Definition of residue on which MRL was set: (c) Spectinomycin

3.2 (a) Commodity: (a) Liver (cattle, pigs & chickens)
(b) MRL: (b) 2000 µg/kg (Temporary)
(c) Definition of residue on which MRL was set: (c) Spectinomycin

3.3 (a) Commodity: (a) Kidney (cattle, pigs & chickens)
(b) MRL: (b) 5000 µg/kg (Temporary)
(c) Definition of residue on which MRL was set:

3.4 (a) Commodity: (a) Fat (cattle, pigs & chickens)
(b) MRL:
(c) Definition of residue on which MRL was set:

3.5 (a) Commodity: (a) Milk (cattle)
(b) MRL:
(c) Definition of residue on which MRL was set:

4. Reference to recommended method(s) of analysis

5. Reference to JECFA Reports:
   WHO TRS 851 (1995)
   WHO FAS 33 (1994)
   FAO FNP 41/6 (1994)

6. Reference to previous Codex Reports:
   Appendix V, ALINORM 95/31

1. **Substance: Spiramycin**

2. Acceptable Daily Intake (ADI) as established by JECFA
   0-50 μg/kg body weight

3.1 (a) Commodity: (a) Liver (pigs)
(b) MRL:
(c) Definition of residue on which MRL was set:

3.2 (a) Commodity: (a) Kidney (pigs)
(b) MRL:
(c) Definition of residue on which MRL was set:

3.3 (a) Commodity: (a) Fat (pigs)
(b) MRL:
(c) Definition of residue on which MRL was set:

4. Reference to recommended method(s) of analysis
   Weil, A., Rhone Merieux, Toulouse, France
   (muscle, liver, kidney, fat/cattle, poultry)

5. Reference to JECFA Reports:
   WHO TRS 815 (1991)
   WHO FAS 29 (1991)
   FAO FNP 41/4 (1991)
   WHO TRS 855 (1995)
   WHO FAS 34 (1995)
   FAO FNP 41/7 (1995)

6. Reference to previous Codex Reports:
   Appendix V, ALINORM 93/31
   Appendix V, ALINORM 93/31A
   Appendix V, ALINORM 95/31
PRIORITY LIST OF VETERINARY DRUGS REQUIRING EVALUATION OR REEVALUATION

1. Substances proposed for evaluation at the 47th meeting of JECFA in June 1996
   - Abamectin (residues)*
   - Ceftiofur sodium (residues)*
   - Chlortetracycline (residues)*
   - Oxytetracycline (residues)*
   - Tetracycline (residues)*
   - Clenbuterol
   - Cypermethrin
   - α-Cypermethrin
   - Neomycin (toxicology)*
   - Porcine somatotropin
   - Spectinomycin (residues)*
   - Spiramycin (residues)*
   - Thiamphenicol
   - Tilmicosin
   - Xylazine

2. Substances provisionally proposed for evaluation at the 48th meeting of JECFA in February 1997
   - Cyfluthrin
   - Danofloxacin
   - Dexamethasone (methodology)*
   - Dihydrostreptomycin*
   - Streptomycin*
   - Enrofloxacin*
   - Fluazuron
   - Flumequine*
   - Gentamicin*
   - Imidocarb
   - Thiabendazole (toxicology)*

3. Substances provisionally proposed for evaluation at the 50th meeting of JECFA in February 1998
   - Azaperone*
   - Diclazuril*
   - Febantel*
   - Fenbendazole*
   - Oxfendazole*
   - Metrifonate
   - Moxidectin*
   - Olaquindox (residues)*

* reevaluation.

Note: Of all the substances on the CCRVDF Priority List, only nicarbazin is not scheduled for review by JECFA. The timing of the review depends on the availability of relevant data.
AMENDMENTS OF METHODS OF ANALYSIS FOR
EXISTING CODEX MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(Recommendations from the 9th Session)

1. Change of the status from provisional to full recommendation

Sulfadimidine: AOAC 993.32.

2. New methods provisionally recommended

Isometamidium: Weil, A., Rhône Mérieux, Toulouse, France (muscle, liver, kidney, fat/cattle)

Oxytetracycline: AOAC 995.04 (milk/cattle)
AOAC 995.09 (muscle, kidney/cattle, pig, poultry)

3. Withdrawal of methods with provisional status

Albendazole: Anonymous, SmithKline Beecham, Inc. (muscle, fat, milk)


LIST OF VETERINARY DRUGS EVALUATED BY JECFA
ON WHICH NO ACTION HAS BEEN TAKEN BY THE COMMITTEE

NOTE: The current list indicates those substances evaluated by JECFA for which no maximum residue level could be recommended by the Expert Committee. The most usual reason for not establishing an MRL was the inadequacy of data provided to JECFA for evaluation. However, it is essential to consult the Expert Committee report for a full understanding of the status of the substance concerned.

<table>
<thead>
<tr>
<th>Substance</th>
<th>JECFA Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloramphenicol</td>
<td>42nd Session, TRS 851 (1995)</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>38th Session, TRS 815 (1991)</td>
</tr>
<tr>
<td>Dimetridazole</td>
<td>34th Session, TRS 788 (1989)</td>
</tr>
<tr>
<td>Furazolidone</td>
<td>40th Session, TRS 832 (1993)</td>
</tr>
<tr>
<td>Ipronidazole</td>
<td>34th Session, TRS 788 (1989)</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>34th Session, TRS 788 (1989)</td>
</tr>
<tr>
<td>Nitrofurazone</td>
<td>40th Session, TRS 832 (1993)</td>
</tr>
<tr>
<td>Oxolinic Acid</td>
<td>43rd Session, TRS 855 (1995)</td>
</tr>
<tr>
<td>Propionylpromazine</td>
<td>38th Session, TRS 815 (1991)</td>
</tr>
<tr>
<td>Ractopamine</td>
<td>40th Session, TRS 832 (1993)</td>
</tr>
<tr>
<td>Ronidazole</td>
<td>42nd Session, TRS 851 (1995)</td>
</tr>
<tr>
<td>Sulfathiazole</td>
<td>34th Session, TRS 788 (1989)</td>
</tr>
<tr>
<td>Tylosin</td>
<td>38th Session, TRS 815 (1991)</td>
</tr>
</tbody>
</table>

Note: Although there have been no maximum residue levels recommended for abamectin, enrofloxacin, flumequine and olaquindox, these are not included in the "Inactive List" as they are provisionally scheduled for evaluation by JECFA.